<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Macrolide antibiotics for bronchiectasis - Kelly, C - 2018 | Cochrane Library</title> <meta content="Macrolide antibiotics for bronchiectasis - Kelly, C - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012406.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Macrolide antibiotics for bronchiectasis - Kelly, C - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012406.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012406.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Macrolide antibiotics for bronchiectasis" name="citation_title"/> <meta content="Carol Kelly" name="citation_author"/> <meta content="James D Chalmers" name="citation_author"/> <meta content="University of Dundee, Ninewells Hospital and Medical School" name="citation_author_institution"/> <meta content="Iain Crossingham" name="citation_author"/> <meta content="East Lancashire Hospitals NHS Trust" name="citation_author_institution"/> <meta content="Nicola Relph" name="citation_author"/> <meta content="Lambert M Felix" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="David J Evans" name="citation_author"/> <meta content="Hemel Hempstead Hospital" name="citation_author_institution"/> <meta content="Stephen J Milan" name="citation_author"/> <meta content="Lancaster University" name="citation_author_institution"/> <meta content="Sally Spencer" name="citation_author"/> <meta content="spencesa@edgehill.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD012406.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/03/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012406.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012406.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012406.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti‐Bacterial Agents [adverse effects, *therapeutic use]; Azithromycin [adverse effects, therapeutic use]; Bronchiectasis [*drug therapy]; Clarithromycin [adverse effects, therapeutic use]; Erythromycin [administration &amp; dosage, therapeutic use]; Macrolides [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Roxithromycin [adverse effects, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012406.pub2&amp;doi=10.1002/14651858.CD012406.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ZDBB8PHY";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012406\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012406\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012406\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012406\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012406.pub2",title:"Macrolide antibiotics for bronchiectasis",firstPublishedDate:"Mar 15, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZDBB8PHY&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012406.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012406.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012406.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012406.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012406.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012406.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012406.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012406.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012406.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012406.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5744 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012406.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/full#CD012406-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/full#CD012406-sec-0120"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/full#CD012406-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/full#CD012406-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/full#CD012406-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/full#CD012406-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/full#CD012406-sec-0047"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/full#CD012406-sec-0114"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/appendices#CD012406-sec-0125"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/table_n/CD012406StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/table_n/CD012406StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Macrolide antibiotics for bronchiectasis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/information#CD012406-cr-0002">Carol Kelly</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/information#CD012406-cr-0003">James D Chalmers</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/information#CD012406-cr-0004">Iain Crossingham</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/information#CD012406-cr-0005">Nicola Relph</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/information#CD012406-cr-0006">Lambert M Felix</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/information#CD012406-cr-0007">David J Evans</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/information#CD012406-cr-0008">Stephen J Milan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012406.pub2/information#CD012406-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>Sally Spencer</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/information/en#CD012406-sec-0141">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 March 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012406.pub2">https://doi.org/10.1002/14651858.CD012406.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012406-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012406-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012406-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012406-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012406-abs-0001" lang="en"> <section id="CD012406-sec-0001"> <h3 class="title" id="CD012406-sec-0001">Background</h3> <p>Bronchiectasis is a chronic respiratory disease characterised by abnormal and irreversible dilatation and distortion of the smaller airways. Bacterial colonisation of the damaged airways leads to chronic cough and sputum production, often with breathlessness and further structural damage to the airways. Long‐term macrolide antibiotic therapy may suppress bacterial infection and reduce inflammation, leading to fewer exacerbations, fewer symptoms, improved lung function, and improved quality of life. Further evidence is required on the efficacy of macrolides in terms of specific bacterial eradication and the extent of antibiotic resistance. </p> </section> <section id="CD012406-sec-0002"> <h3 class="title" id="CD012406-sec-0002">Objectives</h3> <p>To determine the impact of macrolide antibiotics in the treatment of adults and children with bronchiectasis. </p> </section> <section id="CD012406-sec-0003"> <h3 class="title" id="CD012406-sec-0003">Search methods</h3> <p>We identified trials from the Cochrane Airways Trials Register, which contains studies identified through multiple electronic searches and handsearches of other sources. We also searched trial registries and reference lists of primary studies. We conducted all searches on 18 January 2018. </p> </section> <section id="CD012406-sec-0004"> <h3 class="title" id="CD012406-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) of at least four weeks' duration that compared macrolide antibiotics with placebo or no intervention for the long‐term management of stable bronchiectasis in adults or children with a diagnosis of bronchiectasis by bronchography, plain film chest radiograph, or high‐resolution computed tomography. We excluded studies in which participants had received continuous or high‐dose antibiotics immediately before enrolment or before a diagnosis of cystic fibrosis, sarcoidosis, or allergic bronchopulmonary aspergillosis. Our primary outcomes were exacerbation, hospitalisation, and serious adverse events. </p> </section> <section id="CD012406-sec-0005"> <h3 class="title" id="CD012406-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened the titles and abstracts of 103 records. We independently screened the full text of 40 study reports and included 15 trials from 30 reports. Two review authors independently extracted outcome data and assessed risk of bias for each study<i>.</i> We analysed dichotomous data as odds ratios (ORs) and continuous data as mean differences (MDs) or standardised mean differences (SMDs). We used standard methodological procedures as expected by Cochrane. </p> </section> <section id="CD012406-sec-0006"> <h3 class="title" id="CD012406-sec-0006">Main results</h3> <p>We included 14 parallel‐group RCTs and one cross‐over RCT with interventions lasting from 8 weeks to 24 months. Of 11 adult studies with 690 participants, six used azithromycin, four roxithromycin, and one erythromycin. Four studies with 190 children used either azithromycin, clarithromycin, erythromycin, or roxithromycin. </p> <p>We included nine adult studies in our comparison between macrolides and placebo and two in our comparison with no intervention. We included one study with children in our comparison between macrolides and placebo and one in our comparison with no intervention. </p> <p>In adults, macrolides reduced exacerbation frequency to a greater extent than placebo (OR 0.34, 95% confidence interval (CI) 0.22 to 0.54; 341 participants; three studies; I<sup>2</sup> = 65%; moderate‐quality evidence). This translates to a number needed to treat for an additional beneficial outcome of 4 (95% CI 3 to 8). Data show no differences in exacerbation frequency between use of macrolides (OR 0.31, 95% CI 0.08 to 1.15; 43 participants; one study; moderate‐quality evidence) and no intervention. Macrolides were also associated with a significantly better quality of life compared with placebo (MD ‐8.90, 95% CI ‐13.13 to ‐4.67; 68 participants; one study; moderate‐quality evidence). We found no evidence of a reduction in hospitalisations (OR 0.56, 95% CI 0.19 to 1.62; 151 participants; two studies; I<sup>2</sup> = 0%; low‐quality evidence), in the number of participants with serious adverse events, including pneumonia, respiratory and non‐respiratory infections, haemoptysis, and gastroenteritis (OR 0.49, 95% CI 0.20 to 1.23; 326 participants; three studies; I<sup>2</sup> = 0%; low‐quality evidence), or in the number experiencing adverse events (OR 0.83, 95% CI 0.51 to 1.35; 435 participants; five studies; I<sup>2</sup> = 28%) in adults with macrolides compared with placebo. </p> <p>In children, exacerbation frequency was reduced more with macrolides than with placebo (IRR 0.50, 95% CI 0.35 to 0.71; 89 children; one study; low‐quality evidence). However there was no significant difference in this age group with regard to: hospitalisations (OR 0.28, 95% CI 0.07 to 1.11; 89 children; one study; low‐quality evidence), serious adverse events, defined within the study as exacerbations of bronchiectasis or investigations related to bronchiectasis (OR 0.43, 95% CI 0.17 to 1.05; 89 children; one study; low‐quality evidence), or adverse events (OR 0.78, 95% CI 0.33 to 1.83; 89 children; one study), in those receiving macrolides compared to placebo. The same study reported an increase in macrolide‐resistant bacteria (OR 7.13, 95% CI 2.13 to 23.79; 89 children; one study), an increase in resistance to <i>Streptococcus pneumoniae</i> (OR 13.20, 95% CI 1.61 to 108.19; 89 children; one study), and an increase in resistance to <i>Staphylococcus aureus</i> (OR 4.16, 95% CI 1.06 to 16.32; 89 children; one study) with macrolides compared with placebo. Quality of life was not reported in the studies with children. </p> </section> <section id="CD012406-sec-0007"> <h3 class="title" id="CD012406-sec-0007">Authors' conclusions</h3> <p>Long‐term macrolide therapy may reduce the frequency of exacerbations and improve quality of life, although supporting evidence is derived mainly from studies of azithromycin, rather than other macrolides, and predominantly among adults rather than children. However, macrolides should be used with caution, as limited data indicate an associated increase in microbial resistance. Macrolides are associated with increased risk of cardiovascular death and other serious adverse events in other populations, and available data cannot exclude a similar risk among patients with bronchiectasis. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012406-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012406-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012406-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012406-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012406-abs-0004">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012406-abs-0003" lang="en"> <h3>Macrolide antibiotics for bronchiectasis</h3> <p><b>Background to the question</b> </p> <p>Bronchiectasis is a long‐term respiratory condition. The airways in the lungs are damaged, and people are prone to infection. Symptoms are chronic cough and the production of sputum (coughed‐up material (phlegm) from the lower airways). Moreover, bronchiectasis is associated with a mortality rate more than twice that of the general population. </p> <p>Long‐term antibiotic therapy with macrolides (such as azithromycin, roxithromycin, erythromycin, and clarithromycin) may reduce the cycle of reinfection, reduce symptoms, and improve quality of life. We wanted to do this review to look at the evidence on use of macrolides in people with bronchiectasis. This review is intended to help people such as guideline producers, doctors, and patients make decisions about whether to use or recommend macrolides. </p> <p><b>Study characteristics</b> </p> <p>We found 15 studies that compared macrolides with placebo (a substance or treatment with no benefit) or no intervention. Eleven studies involved 690 adults (aged 18 years and older) and four studies involved 190 children. Among adults, six used azithromycin, four roxithromycin, and one erythromycin. The four studies with children used azithromycin, clarithromycin, erythromycin, or roxithromycin. This review is current to January 2018. </p> <p><b>Main results</b> </p> <p>The studies on azithromycin reported improved quality of life in adults. We do not have sufficient evidence from other macrolides to make a robust judgement on their use, and we similarly have insufficient evidence from children to draw clear conclusions. </p> <p>Although we found only a few trials, they do show a possible increase in antibiotic resistance. Antibiotic resistance is seen when an antibiotic becomes less effective at killing the bacteria causing the chest infection. </p> <p>We know that macrolides are associated with higher risk of cardiovascular death and other serious adverse events when they are used to treat other conditions. The data in our review suggest it is possible that people with bronchiectasis are at risk for these adverse effects when taking macrolides. </p> <p><b>Quality of the evidence</b> </p> <p>Generally the limited number of studies evaluating macrolides and the variation among them indicate that we cannot be sure of the overall effect of their use in bronchiectasis. Further high‐quality studies are needed to examine the role of long‐term macrolide antibiotics in the treatment of adults and children with bronchiectasis. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012406-sec-0120" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012406-sec-0120"></div> <h3 class="title" id="CD012406-sec-0121">Implications for practice</h3> <section id="CD012406-sec-0121"> <p>This review includes 11 studies with 690 adults and four studies with 190 children. Long‐term macrolide therapy is an option for patients with bronchiectasis with the aim of reducing the rate of exacerbations and improving quality of life. Supporting evidence is derived mainly from studies of azithromycin, rather than other macrolides, and predominantly in adults rather than in children. However, macrolides should be used with caution, as limited data support an increase in microbial resistance with macrolides. Macrolides have been associated with excessive risk of cardiovascular death and other serious adverse events in populations other than individuals with bronchiectasis (<a href="./references#CD012406-bbs2-0053" title="RayWA , MurrayKT , HallK , ArbogastPG , SteinCM . Azithromycin and the risk of cardiovascular death. New England Journal of Medicine2012;366:1881‐90. ">Ray 2012</a>), and available data cannot exclude a similar risk in patients with bronchiectasis. The presence of non‐tuberculous mycobacteria (NTM) should be identified in all patients before long‐term macrolide therapy is begun. </p> </section> <h3 class="title" id="CD012406-sec-0122">Implications for research</h3> <section id="CD012406-sec-0122"> <p>The present review highlights several outstanding questions on long‐term macrolide treatment in clinical practice. Although macrolides significantly reduced exacerbations, studies used different macrolide drugs at different doses. As a result, we are unable to recommend the most appropriate agent, dose, or administration schedule (daily vs intermittent) for long‐term therapy. Doses ranging from 250 mg three times per week to 500 mg daily have been reported in clinical practice. </p> <p>The European Bronchiectasis Network (EMBARC) recently published a series of research priorities, which included several related to macrolide treatment. Recognising the limitations of existing data, EMBARC recommended longer‐term studies to evaluate the development of antibiotic resistance as well as long‐term safety. Further studies conducted to determine whether macrolides should be administered continuously or in a cyclical pattern (as during the winter, when exacerbations occur more frequently) would help guide clinical practice. The optimal patient population to benefit from macrolides has not been identified, as each of the macrolide studies was too small to allow meaningful subgroup or 'responder' analyses. It is unclear whether macrolide therapy is suitable for all patients with bronchiectasis, and macrolides have important side effects, including the risk of inducing antibiotic resistance; thus, EMBARC has recommended further research to target these topics more effectively. </p> <p>Existing studies and meta‐analyses have largely taken the view that macrolide efficacy in bronchiectasis has been proven, and that additional large studies are unnecessary. Our results suggest that substantial uncertainties about macrolide efficacy remain, particularly with regard to improvements in quality of life and lung function, as well as impact on antimicrobial resistance. In addition, the relative benefits of macrolides compared with those of other types of antibiotics are unknown, as we did not identify any studies that included these comparisons. Our analysis suggests that additional large, randomised, placebo controlled trials should be performed to confirm the efficacy and safety of macrolides. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012406-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012406-sec-0015"></div> <div class="table" id="CD012406-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Macrolides compared with placebo for adults with bronchiectasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Macrolides compared with placebo for adults with bronchiectasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with bronchiectasis<br/> <b>Setting:</b> outpatient clinics in Australia, Azerbaijan, Malaysia, Netherlands, New Zealand, and Thailand<br/> <b>Intervention:</b> macrolides<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with macrolides</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 1 exacerbation<br/> Follow‐up: range 24 weeks to 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>714 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>459 per 1000<br/> (355 to 574) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.34<br/> (0.22 to 0.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies azithromycin (1750 mg/week for 52 weeks; 1500 mg/week for 6 months) 1 study erythromycin (3500 mg/week for 48 weeks) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation: all cause<br/> Follow‐up: range 12 weeks to 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>133 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000<br/> (28 to 200) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.56<br/> (0.19 to 1.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies azithromycin (1000 mg/week for 12 weeks; 1750 mg/week for 52 weeks)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/> Follow‐up: range 24 weeks to 48 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000<br/> (18 to 104) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.49<br/> (0.20 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>326<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies azithromycin (1500 mg/week for 6 months; 1000 mg/week for 12 weeks) 1 study erythromycin (3500 mg/week for 48 weeks) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality<br/> Follow‐up: range 8 weeks to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>540<br/> (7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>e,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies azithromycin (1000 to 1750 mg/week for 12 to 52 weeks)<br/> 2 studies roxithromycin (2100 mg/week for 8 to 12 weeks)<br/> 1 study erythromycin (3500 mg/week for 48 weeks) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life: endpoint<br/> assessed with SGRQ<br/> Scale from 0 to 100<br/> Follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean SGRQ score at endpoint in placebo groups was 39.1 points.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 8.90 lower (13.13 lower to 4.67 lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<br/> (1 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study azithromycin (1000 mg/week for 12 weeks)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life: change<br/> assessed with SGRQ<br/> Scale from 0 to 100<br/> Follow‐up: range 8 weeks to 48 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in SGRQ score ranged from ‐1.3 to ‐8.9 points.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.86 lower<br/> (5.67 lower to 0.04 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>305<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>g,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study azithromycin (1500 mg/week for 6 months)<br/> 1 study erythromycin (3500 mg/week for 48 weeks)<br/> 2 studies roxithromycin (2100 mg/week for 12 weeks; 2100 mg/week for 8 weeks) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI</b> : confidence interval; <b>OR</b> : odds ratio; <b>RCT</b> : randomised controlled trial; <b>RR</b> : risk ratio; <b>SGRQ</b>: St. George's Respiratory Questionnaire. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Effect observed only with azithromycin (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> <p><sup>b</sup>Unclear allocation concealment and baseline imbalances on Lourdesamy (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> <p><sup>c</sup>Two small studies and wide confidence interval (one point deducted for imprecision). </p> <p><sup>d</sup>Wide confidence interval (one point deducted for imprecision). </p> <p><sup>e</sup>In three of the seven studies, study methods were not clearly reported (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> <p><sup>f</sup>A total of 28 participants across four studies were lost to follow‐up with no further details available and unclear details of withdrawals in one study (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> <p><sup>g</sup>Randomisation, blinding, and other study methods unclear in two studies (Asintam; Juthong) (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> <p><sup>h</sup>Wide confidence interval and mean difference does not exceed the threshold for clinical significance (one point deducted for imprecision). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012406-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Macrolides compared with no intervention for adults with bronchiectasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Macrolides compared with no intervention for adults with bronchiectasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with bronchiectasis<br/> <b>Setting:</b> outpatient clinics in China and Spain<br/> <b>Intervention:</b> macrolides<br/> <b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with macrolides</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>≥ 1 exacerbation<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.31<br/> (0.08 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>43<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Roxithromycin (1050 mg/week for 6 months)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>762 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>498 per 1000<br/> (204 to 786) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisations ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality<br/> Follow‐up: range 3 months to 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No deaths in two trials, although in 1 study (azithromycin), 6 participants were lost to follow‐up </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study azithromycin (750 mg/week for 3 months)<br/> 1 study roxithromycin (1050 mg/week for 6 months) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QoL SGRQ: endpoint total score<br/> Scale from 0 to 100<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean SGRQ: endpoint total score of 51.7 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 8.81 lower (14.33 lower to 3.28 lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89<br/> (2 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study roxithromycin (1050 mg/week for 6 months)<br/> 1 study roxithromycin (1050 mg/week for 6 months) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QoL SGRQ: change in total score<br/> Scale from 0 to 100<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean SGRQ: change in total score of 4.1</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 12 lower<br/> (21.61 lower to 2.39 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (750 mg/week for 3 months)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI</b> : confidence interval; <b>MD</b> : mean difference; <b>RCT</b> : randomised controlled trial; <b>RR</b> : risk ratio; <b>OR</b> : odds ratio; <b>QoL</b> : quality of life; <b>SGRQ</b>: St. George's Respiratory Questionnaire. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Open‐label study (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> <p><sup>b</sup>Unclear randomisation and study methods (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> <p><sup>c</sup>6 participants in one study lost to follow‐up and no further details reported (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012406-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Macrolides compared with placebo for children with bronchiectasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Macrolides compared with placebo for children with bronchiectasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children with bronchiectasis<br/> <b>Setting:</b> outpatient clinics in Australia, New Zealand, and South Africa<br/> <b>Intervention:</b> macrolides<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with macrolides</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation frequency</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Number of exacerbations 195 (median: 4 range 0‐14)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Number of exacerbations 104 (median: 2 range 0‐9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRR 0.50 95% CI 0.35 to 0.71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (30 mg/kg/week for up to 24 months)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation: all‐cause<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>205 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000<br/> (18 to 222) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.28<br/> (0.07 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (30 mg/kg/week for 24 months)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>432 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>246 per 1000<br/> (114 to 444) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.43<br/> (0.17 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (30 mg/kg/week for 24 months)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 child died but study group was not stated.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin (875 to 1750 mg/kg/week for 52 weeks)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI</b> : confidence interval; <b>IRR</b> : incidence rate ratio; <b>OR</b> : odds ratio; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Wide confidence interval that includes 1 (no difference) (one point deducted for imprecision). </p> <p><sup>b</sup>Low event rates and low numbers (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> <p><sup>c</sup>Unclear information on randomisation, blinding, and other study methods (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> <p><sup>d</sup>No information on participants lost to follow‐up (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012406-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Macrolides compared with no intervention for children with bronchiectasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Macrolides compared with no intervention for children with bronchiectasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children with bronchiectasis<br/> <b>Setting:</b> outpatient clinic in Turkey<br/> <b>Intervention:</b> macrolides<br/> <b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with macrolides</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbations ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clarithromycin (105 mg/kg/week for 3 months)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI</b> : confidence interval; <b>RCT</b>: randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Insufficient information on study methods and procedures (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> <p><sup>b</sup>Not blinded (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012406-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012406-sec-0016"></div> <section id="CD012406-sec-0017"> <h3 class="title" id="CD012406-sec-0017">Description of the condition</h3> <p>Bronchiectasis is a chronic respiratory disease characterised by abnormal and irreversible dilatation and distortion of the airways (<a href="./references#CD012406-bbs2-0051" title="PasteurMC , BiltonD , HillAT , British Thoracic Society Bronchiectasis (non‐CF) Guideline Group. British Thoracic Society Guidelines for Non‐CF Bronchiectasis. Thorax2010;65(Suppl 1):i1‐58. ">Pasteur 2010</a>). Bacterial colonisation of the damaged airways leads to chronic cough and sputum production, often with breathlessness and further structural damage to the airways. Diagnosis is made by computed tomography (CT) scanning of the chest when appropriate clinical symptoms are identified (<a href="./references#CD012406-bbs2-0032" title="ChangAB , BellSC , ByrnesCA , GrimwoodK , HolmesP , KingPT , et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand: a position statement from the Thoracic Society of Australia and New Zealand and the Australian Lung Foundation. Medical Journal of Australia2010;193(6):356‐65. ">Chang 2010</a>), but asymptomatic radiological evidence of bronchiectasis may be noted (<a href="./references#CD012406-bbs2-0046" title="KwakHJ , MoonJY , ChoiYW , KimTH , SohnJW , YoonHJ , et al. High prevalence of bronchiectasis in adults: analysis of CT findings in a health screening program. Tohoku Journal of Experimental Medicine2010;222(4):237‐42. ">Kwak 2010</a>). </p> <p>Bronchiectasis has many causes, generally involving major or repeated insults to the lungs. Severe infections including pneumonia, tuberculosis, and pertussis may cause bronchiectasis, particularly if they occur during childhood while the lungs are still developing. Connective tissue disorders and defects in the immune system are other common causes of bronchiectasis, but many cases are idiopathic. Cystic fibrosis leads to severe, progressive bronchiectasis and usually is considered a separate entity from 'non‐cystic fibrosis' bronchiectasis. This review will exclude bronchiectasis secondary to cystic fibrosis. </p> <p>Prevalence estimates are unclear owing to variable diagnostic strategies (<a href="./references#CD012406-bbs2-0063" title="WeyckerD , EdelsbergJ , OsterG , TinoG . Prevalence and economic burden of bronchiectasis. Clinical Pulmonary Medicine2005;12(4):205‐9. ">Weycker 2005</a>), a well as higher prevalence rates in developing countries (<a href="./references#CD012406-bbs2-0038" title="HabesogluMA , UgurluAO , EyubogluFO . Clinical, radiologic, and functional evaluation of 304 patients with bronchiectasis. Annals of Thoracic Medicine2011;6(3):131‐6. ">Habesoglu 2011</a>), but the global disease burden is increasing, with mortality rising by 3% per year between 2001 and 2007, in England and in Wales (<a href="./references#CD012406-bbs2-0056" title="RobertsHJ , HubbardR . Trends in bronchiectasis mortality in England and Wales. Respiratory Medicine2010;104:981‐5. ">Roberts 2010</a>), and hospitalisations by 3% per year in the United States (<a href="./references#CD012406-bbs2-0058" title="SeitzAE , OlivierKN , SteinerCA , Montes de OcaR , HollandSM , PrevotsDR . Trends and burden of bronchiectasis‐associated hospitalizations in the United States. Chest2010;138:944‐9. ">Seitz 2010</a>). Prevalence is higher in women and those over 60 years of age (<a href="./references#CD012406-bbs2-0056" title="RobertsHJ , HubbardR . Trends in bronchiectasis mortality in England and Wales. Respiratory Medicine2010;104:981‐5. ">Roberts 2010</a>; <a href="./references#CD012406-bbs2-0059" title="SeitzAE , OlivierKN , AdjemianJ , HollandSM , PrevotsDR . Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000‐2007. Chest2012;142(2):432‐9. ">Seitz 2012</a>). However, prevalence rates may be increasing more rapidly than was previously estimated, with 67 cases per 100,000 general population reported in Germany (<a href="./references#CD012406-bbs2-0055" title="RingshausenFC , deRouxA , DielR , HohmannD , WelteT , RademacherJ . Bronchiectasis in Germany: a population‐based estimation of disease prevalence. European Respiratory Journal2015;46(6):1805‐7. [PUBMED: 26293498] ">Ringshausen 2015</a>), and with UK prevalence rising from 350.5 to 566.1 in women and from 301.2 to 485.5 in men, affecting around 262,900 adults (<a href="./references#CD012406-bbs2-0052" title="QuintJK , MillettERC , JoshiM , NavaratnamV , ThomasSL , HurstJR , et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population‐based cohort study. European Respiratory Journal2016;47(1):186‐93. [DOI: 10.1183/13993003.01033‐2015] ">Quint 2016</a>). Similarly, UK incidence rates increased by 63% over nine years to 2013, rising from 21.2 to 35.2 in women and 8.2 to 26.9 in men, per 100,000 person‐years (<a href="./references#CD012406-bbs2-0052" title="QuintJK , MillettERC , JoshiM , NavaratnamV , ThomasSL , HurstJR , et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population‐based cohort study. European Respiratory Journal2016;47(1):186‐93. [DOI: 10.1183/13993003.01033‐2015] ">Quint 2016</a>). In paediatric populations, younger children and more frequent exacerbations are associated with worse quality of life (<a href="./references#CD012406-bbs2-0044" title="KapurN , MastersIB , NewcombeP , ChangAB . The burden of disease in pediatric non‐cystic fibrosis bronchiectasis. Chest2012;141(4):1018‐24. [PUBMED: 21885727] ">Kapur 2012</a>). A higher prevalence of bronchiectasis has been reported among indigenous children in Australia (15:1000) and Alaska (16:1000) (<a href="./references#CD012406-bbs2-0031" title="ChangAB , GrimwoodK , MulhollandEK , TorzilloPJ . Bronchiectasis in indigenous children in remote Australian communities. Medical Journal of Australia2002;177(4):200‐4. [PUBMED: 12175325] ">Chang 2002</a>). Incidence rates of 3.7 per 10,000 per year in children under 15 years of age have been reported in New Zealand (<a href="./references#CD012406-bbs2-0061" title='TwissJ , MetcalfeR , EdwardsE , ByrnesC . New Zealand national incidence of bronchiectasis "too high" for a developed country. Archives of Disease in Childhood2005;90(7):737‐40. [PUBMED: 15871981] '>Twiss 2005</a>). This equates to a prevalence of 1:3000 children overall and 1:625 children of Pacific Island descent (<a href="./references#CD012406-bbs2-0061" title='TwissJ , MetcalfeR , EdwardsE , ByrnesC . New Zealand national incidence of bronchiectasis "too high" for a developed country. Archives of Disease in Childhood2005;90(7):737‐40. [PUBMED: 15871981] '>Twiss 2005</a>). However, these increases may be due to improved diagnosis resulting from easier access to high‐quality CT scanners, rather than reflecting a true rise in prevalence (<a href="./references#CD012406-bbs2-0036" title="GoeminnePC , DeSoyzaA . Bronchiectasis: how to be an orphan with many parents?. European Respiratory Journal2016;47(1):10‐3. ">Goeminne 2016</a>). </p> <p>Estimated European mortality rates are 0.3 per 100,000 general population in EU countries (ranging from 0.01 in Germany to 1.18 in the UK) and 0.2 per 100,000 in non‐EU countries (ranging from 0.01 in Azerbaijan to 0.67 in Kyrgyzstan), based on data to 2009 (<a href="./references#CD012406-bbs2-0033" title="GibsonGJ , LoddenkemperR , SibilleY , LundbäckB , editor(s) . European Lung White Book: Respiratory Health and Disease in Europe. European Respiratory Society, 2013. https://www.erswhitebook.org/ (accessed before 11 January 2018). ">European Lung White Book 2013</a>). Recent age‐adjusted mortality rates in the UK are estimated to be 2.26 times higher in women and 2.14 times higher in men compared with the wider population (<a href="./references#CD012406-bbs2-0052" title="QuintJK , MillettERC , JoshiM , NavaratnamV , ThomasSL , HurstJR , et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population‐based cohort study. European Respiratory Journal2016;47(1):186‐93. [DOI: 10.1183/13993003.01033‐2015] ">Quint 2016</a>). This information is based on estimated mortality rates for bronchiectasis of 1437.7 per 100,000 and for the general population of 635.9 per 100,000 (<a href="./references#CD012406-bbs2-0052" title="QuintJK , MillettERC , JoshiM , NavaratnamV , ThomasSL , HurstJR , et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population‐based cohort study. European Respiratory Journal2016;47(1):186‐93. [DOI: 10.1183/13993003.01033‐2015] ">Quint 2016</a>). </p> </section> <section id="CD012406-sec-0018"> <h3 class="title" id="CD012406-sec-0018">Description of the intervention</h3> <p>Chronic airway infection with pathogens such as <i>Pseudomonas aeruginosa</i> and <i>Haemophilus influenzae</i> and neutrophil‐mediated airway inflammation are key drivers of disease progression and poor outcomes in bronchiectasis (<a href="./references#CD012406-bbs2-0029" title="ChalmersJD , SmithMP , McHughBJ , DohertyC , GovanJR , HillAT . Short‐ and long‐term antibiotic treatment reduces airway and systemic inflammation in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;186(7):657‐65. ">Chalmers 2012</a>; <a href="./references#CD012406-bbs2-0030" title="ChalmersJD , GoeminneP , AlibertiS , MelissaJ , McDonnellMJ , LonniS , et al. The Bronchiectasis Severity Index: an international derivation and validation study. American Journal of Respiratory and Critical Care Medicine2014;189(5):576‐85. [DOI: 10.1164/rccm.201309‐1575OC] ">Chalmers 2014</a>; <a href="./references#CD012406-bbs2-0034" title="FinchS , McDonnellMJ , Abo‐LeyahH , AlibertiS , ChalmersJD . A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Annals of the American Thoracic Society2015;12(11):1602‐11. ">Finch 2015</a>). Long‐term antibiotic therapy therefore is often prescribed with the intention of suppressing bacterial load and reducing airway inflammation (<a href="./references#CD012406-bbs2-0029" title="ChalmersJD , SmithMP , McHughBJ , DohertyC , GovanJR , HillAT . Short‐ and long‐term antibiotic treatment reduces airway and systemic inflammation in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;186(7):657‐65. ">Chalmers 2012</a>). This in turn aims to reduce exacerbations, improve symptoms, and improve quality of life (<a href="./references#CD012406-bbs2-0040" title="HaworthCS , BiltonD , ElbornJS . Long term macrolide maintenance therapy in non‐CF bronchiectasis: evidence and questions. Respiratory Medicine2014;108(1):1397‐408. ">Haworth 2014</a>). Prolonged antibiotic treatment can be administered in the form of oral or inhaled antibiotics. Inhaled antibiotics offer the advantage of delivering a higher dose of the drug directly to the site of bronchiectasis infection, with less potential for collateral damage and resistance; however, they are often time consuming to administer (<a href="./references#CD012406-bbs2-0028" title="BrodtAM , StovoldE , ZhangL . Inhaled antibiotics for stable non‐cystic fibrosis bronchiectasis: a systematic review. European Respiratory Journal2014;44(2):382‐93. ">Brodt 2014</a>). Oral antibiotics by contrast are typically cheaper and easier to administer than inhaled antibiotics. </p> <p>Oral antibiotics may be given at lower doses than those used to treat acute infection, with the aims of reducing adverse effects and promoting compliance (<a href="./references#CD012406-bbs2-0040" title="HaworthCS , BiltonD , ElbornJS . Long term macrolide maintenance therapy in non‐CF bronchiectasis: evidence and questions. Respiratory Medicine2014;108(1):1397‐408. ">Haworth 2014</a>). Macrolide antibiotics are antibacterial agents with anti‐inflammatory and immunomodulatory properties (<a href="./references#CD012406-bbs2-0040" title="HaworthCS , BiltonD , ElbornJS . Long term macrolide maintenance therapy in non‐CF bronchiectasis: evidence and questions. Respiratory Medicine2014;108(1):1397‐408. ">Haworth 2014</a>). Long‐acting macrolide antibiotics such as azithromycin can be given intermittently rather than requiring daily dosing. Penicillins, tetracyclines, and macrolides have all been tested as prolonged therapy in bronchiectasis (<a href="./references#CD012406-bbs2-0051" title="PasteurMC , BiltonD , HillAT , British Thoracic Society Bronchiectasis (non‐CF) Guideline Group. British Thoracic Society Guidelines for Non‐CF Bronchiectasis. Thorax2010;65(Suppl 1):i1‐58. ">Pasteur 2010</a>). National guidelines for bronchiectasis, such as those provided by the British Thoracic Society, suggest that use of long‐term antibiotic treatment should be considered for patients with three or more exacerbations per year (<a href="./references#CD012406-bbs2-0051" title="PasteurMC , BiltonD , HillAT , British Thoracic Society Bronchiectasis (non‐CF) Guideline Group. British Thoracic Society Guidelines for Non‐CF Bronchiectasis. Thorax2010;65(Suppl 1):i1‐58. ">Pasteur 2010</a>). </p> <p>Long‐term use of macrolides in bronchiectasis is supported by their ease of administration, their effectiveness in cystic fibrosis and other neutrophilic lung diseases, and their reported anti‐inflammatory properties (<a href="./references#CD012406-bbs2-0057" title="SaimanL , MarshallBC , Mayer‐HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749‐56. ">Saiman 2003</a>). Balanced against these traits is the potential for macrolides to induce antibiotic resistance and produce antibiotic‐related adverse effects, hearing impairment, and cardiotoxicity (<a href="./references#CD012406-bbs2-0060" title="SerisierDJ . Risk of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respiratory Medicine2013;1(3):262‐74. ">Serisier 2013a</a>). </p> </section> <section id="CD012406-sec-0019"> <h3 class="title" id="CD012406-sec-0019">How the intervention might work</h3> <p>Exacerbations, symptoms, and quality of life are directly linked to bacterial infection and airway inflammation in bronchiectasis (<a href="./references#CD012406-bbs2-0029" title="ChalmersJD , SmithMP , McHughBJ , DohertyC , GovanJR , HillAT . Short‐ and long‐term antibiotic treatment reduces airway and systemic inflammation in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;186(7):657‐65. ">Chalmers 2012</a>; <a href="./references#CD012406-bbs2-0030" title="ChalmersJD , GoeminneP , AlibertiS , MelissaJ , McDonnellMJ , LonniS , et al. The Bronchiectasis Severity Index: an international derivation and validation study. American Journal of Respiratory and Critical Care Medicine2014;189(5):576‐85. [DOI: 10.1164/rccm.201309‐1575OC] ">Chalmers 2014</a>). Macrolides are given as both antibacterial and anti‐inflammatory drugs, although it is unclear which of these properties is primarily responsible for the clinical effect observed in cystic fibrosis or bronchiectasis. Macrolides bind reversibly to the 50s ribosomal subunit, preventing bacterial protein synthesis (<a href="./references#CD012406-bbs2-0040" title="HaworthCS , BiltonD , ElbornJS . Long term macrolide maintenance therapy in non‐CF bronchiectasis: evidence and questions. Respiratory Medicine2014;108(1):1397‐408. ">Haworth 2014</a>). They therefore have broad activity against Gram‐positive organisms such as staphylococci and streptococci and exhibit a degree of activity against Gram‐negative organisms such as <i>Haemophilus</i> bacteria<i>.</i> It is interesting to note that macrolides show no bacteriocidal activity against <i>P aeruginosa</i> but may modify virulence by interfering with quorum sensing and virulence factors (<a href="./references#CD012406-bbs2-0045" title="KohlerT , PerronGG , BucklingA , vanDeldenC . Quorum sensing inhibition selects for virulence and co‐operation in Pseudomonas aeruginosa. PLoS Pathogens2010;6(5):e1000883. ">Kohler 2010</a>). </p> <p>The anti‐inflammatory effects of macrolides have been known for decades and are classically demonstrated in their effectiveness against diffuse panbronchiolitis (<a href="./references#CD012406-bbs2-0027" title="AmsdenGW . Anti‐inflammatory effects of macrolides ‐ an underappreciated benefit in the treatment of community‐acquired respiratory tract infections and chronic inflammatory pulmonary conditions?. Journal of Antimicrobial Chemotherapy2005;55(1):10‐21. ">Amsden 2005</a>). Macrolides contain a macrocytic lactone ring that is thought to be responsible for most anti‐inflammatory effects (<a href="./references#CD012406-bbs2-0040" title="HaworthCS , BiltonD , ElbornJS . Long term macrolide maintenance therapy in non‐CF bronchiectasis: evidence and questions. Respiratory Medicine2014;108(1):1397‐408. ">Haworth 2014</a>). Macrolides are classified according to the number of lactone rings as 14‐, 15‐, and 16‐member ring macrolides. Macrolides confer potentially beneficial effects at every level of the 'vicious cycle' of bronchiectasis. They reduce the secretion of pro‐inflammatory cytokines from epithelial cells, inhibit leucocyte recruitment to the airway, inhibit neutrophil activation, and reduce oxidative stress (<a href="./references#CD012406-bbs2-0065" title="ZarogoulidisP , PapanasN , KioumisI , ChatzakiE , MaltezosE , ZarogoulidisK . Macrolides from in vitro anti‐inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. European Journal of Clinical Pharmacology2012;68(5):479‐503. ">Zarogoulidis 2012</a>). </p> <p>Thus potential benefits of macrolides include suppression of bacterial infection, leading to reduced exacerbations, reduced cough and sputum production, and improved lung function and quality of life. </p> </section> <section id="CD012406-sec-0020"> <h3 class="title" id="CD012406-sec-0020">Why it is important to do this review</h3> <p>Bronchiectasis is associated with a mortality rate more than twice that of the general population ‐ 2.26 times higher in women and 2.14 times higher in men (<a href="./references#CD012406-bbs2-0052" title="QuintJK , MillettERC , JoshiM , NavaratnamV , ThomasSL , HurstJR , et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population‐based cohort study. European Respiratory Journal2016;47(1):186‐93. [DOI: 10.1183/13993003.01033‐2015] ">Quint 2016</a>). Data on the economic burden of bronchiectasis are few; however a 2001 US study reported 2.0 more days in hospital, 6.1 more outpatient appointments, and 27.2 more days of antibiotic treatment (<a href="./references#CD012406-bbs2-0063" title="WeyckerD , EdelsbergJ , OsterG , TinoG . Prevalence and economic burden of bronchiectasis. Clinical Pulmonary Medicine2005;12(4):205‐9. ">Weycker 2005</a>). It is estimated that additional annual costs associated with bronchiectasis ranged from USD 5681 to USD 7827 during the period between 2001 and 2009 (<a href="./references#CD012406-bbs2-0043" title="JoishVN , Spilsbury‐CantalupoM , OperschallE , LuongB , BoklageS . Economic burden of non‐cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective. Applied Health Economics and Health Policy2013;11(3):299‐304. ">Joish 2013</a>; <a href="./references#CD012406-bbs2-0058" title="SeitzAE , OlivierKN , SteinerCA , Montes de OcaR , HollandSM , PrevotsDR . Trends and burden of bronchiectasis‐associated hospitalizations in the United States. Chest2010;138:944‐9. ">Seitz 2010</a>; <a href="./references#CD012406-bbs2-0063" title="WeyckerD , EdelsbergJ , OsterG , TinoG . Prevalence and economic burden of bronchiectasis. Clinical Pulmonary Medicine2005;12(4):205‐9. ">Weycker 2005</a>). </p> <p>Frequent exacerbations lead to impaired quality of life and progressive lung damage with permanent loss of lung function (<a href="./references#CD012406-bbs2-0049" title="Martínez‐GarcíaMA , Soler‐CataluñaJJ , Perpiñá‐TorderaM , Román‐SánchezP , SorianoJ . Factors associated with lung function decline in adult patients with stable non‐cystic fibrosis bronchiectasis. Chest2007;132(5):1565‐72. ">Martínez‐García 2007</a>). Therefore, drug interventions that are effective in reducing the frequency of exacerbations should offer both short‐term and long‐term benefit for patients with bronchiectasis. A Cochrane Review of short‐term antibiotics provided little evidence on which to base a recommendation, with one small trial showing evidence of global improvement and pathogen eradication in sputum (<a href="./references#CD012406-bbs2-0064" title="WurzelD , MarchantJM , YerkovichST , UphamJW , MastersIB , ChangAB . Short courses of antibiotics for children and adults with bronchiectasis. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD008695.pub2] ">Wurzel 2011</a>). Another Cochrane Review of long‐term antibiotic therapy included 18 trials of moderate quality and provided evidence of reduced exacerbation frequency and hospitalisation but increased drug resistance (<a href="./references#CD012406-bbs2-0042" title="HninK , NguyenC , CarsonKV , EvansDJ , GreenstoneM , SmithBJ . Prolonged antibiotics for non‐cystic fibrosis bronchiectasis in children and adults. Cochrane Database of Systematic Reviews2015, Issue 8. [DOI: 10.1002/14651858.CD001392.pub3] ">Hnin 2015</a>). Neither of these Cochrane Reviews examined effects by class of antibiotics, and neither specifically created subgroups by macrolide therapy. A Cochrane Overview concluded that further evidence is required on the efficacy of antibiotics in terms of eradication of specific bacterial colonisation and the extent of antibiotic resistance (<a href="./references#CD012406-bbs2-0062" title="WelshEJ , EvansDJ , FowlerSJ , SpencerS . Interventions for bronchiectasis: an overview of Cochrane systematic reviews. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD010337.pub2] ">Welsh 2015</a>). Recent recommendations from the European Task Force on Bronchiectasis further reinforced the importance of this question by identifying research on macrolide therapy as one of the key priorities in bronchiectasis (<a href="./references#CD012406-bbs2-0026" title="AlibertiS , MasefieldS , PolverinoE , DeSoyzaA , LoebingerMR , MenendezR , et al. Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. European Respiratory Journal2016;48(3):632‐47. ">Aliberti 2016</a>). Macrolides may potentially reduce exacerbations of bronchiectasis. Given their drawbacks, particularly cardiac toxicity as described by <a href="./references#CD012406-bbs2-0053" title="RayWA , MurrayKT , HallK , ArbogastPG , SteinCM . Azithromycin and the risk of cardiovascular death. New England Journal of Medicine2012;366:1881‐90. ">Ray 2012</a> and the potential for selecting antibiotic‐resistant organisms as discussed by <a href="./references#CD012406-bbs2-0047" title="LeclercqR . Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clinical Infectious Diseases2002;34(4):482‐92. ">Leclercq 2002</a>, robust evidence on the effectiveness of macrolides is needed if they are to be used with confidence for this indication. </p> <p>This review is being conducted alongside two other, closely related reviews: "Dual antibiotics for bronchiectasis" and<i>"</i>Head to head trials of antibiotics for bronchiectasis". </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012406-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012406-sec-0021"></div> <p>To determine the impact of macrolide antibiotics in the treatment of adults and children with bronchiectasis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012406-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012406-sec-0022"></div> <section id="CD012406-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012406-sec-0024"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) of at least four weeks' duration. We included cross‐over studies but used only data from the first pre‐cross‐over phase to eliminate potentially irreversible carry‐over effects (e.g. antibiotic resistance). We included studies reported as full text, those published as abstract only, and unpublished data. </p> </section> <section id="CD012406-sec-0025"> <h4 class="title">Types of participants</h4> <p>We included adults and children with a diagnosis of bronchiectasis by bronchography, plain film chest radiography, or high‐resolution computed tomography who reported daily sputum expectoration for at least three months. We did not exclude participants whose condition was diagnosed by radiography alone. When a study included participants with different respiratory conditions, we included the study only if investigators performed a separate subgroup analysis for participants with bronchiectasis. We excluded studies if participants had been receiving continuous or high‐dose antibiotics immediately before enrolment, or if they had received a diagnosis of cystic fibrosis, sarcoidosis, or allergic bronchopulmonary aspergillosis. We defined children as individuals from six months to 18 years of age. </p> </section> <section id="CD012406-sec-0026"> <h4 class="title">Types of interventions</h4> <p>We included studies comparing macrolide antibiotics with placebo, no intervention, or non‐macrolide antibiotics for long‐term management of stable bronchiectasis and reporting these different comparisons separately. We excluded studies looking at short‐term macrolides for management (as opposed to prevention) of exacerbations of bronchiectasis. </p> </section> <section id="CD012406-sec-0027"> <h4 class="title">Types of outcome measures</h4> <p>We used exacerbation and hospitalisation rates as reported by study authors. We collected outcome data at a range of follow‐up points that best reflected available evidence from included studies (e.g. end of study, end of follow‐up, change from baseline). </p> <section id="CD012406-sec-0028"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012406-list-0001"> <li> <p>Exacerbations (defined by study authors' criteria)</p> </li> <li> <p>Hospitalisation (defined by study authors' criteria)</p> </li> <li> <p>Serious adverse events defined by <a href="./references#CD012406-bbs2-0039" title="HansenMP , ThorningS , AronsonJK , BellerEM , GlasziouPP , HoffmannTC , et al. Adverse events in patients taking macrolide antibiotics versus placebo for any indication. Cochrane Database of Systematic Reviews2015, Issue 8. [DOI: 10.1002/14651858.CD011825] ">Hansen 2015</a>, as follows: adverse events that result in death or life‐threatening events, requirement for hospitalisation or prolongation of existing hospitalisation, persistent or significant disability, or congenital anomalies; or events that are considered medically important </p> </li> </ol> </p> </section> <section id="CD012406-sec-0029"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012406-list-0002"> <li> <p>Sputum volume and purulence</p> </li> <li> <p>Measures of lung function (e.g. forced expiratory volume in one second (FEV<sub>1</sub>)) </p> </li> <li> <p>Systemic markers of infection (C‐reactive protein (CRP))</p> </li> <li> <p>Adverse events (e.g. cardiac arrhythmias, gastrointestinal symptoms, hearing impairment)</p> </li> <li> <p>Mortality (with this review indicating whether defined as all‐cause or bronchiectasis‐related in individual studies) </p> </li> <li> <p>Emergence of resistance to antibiotics</p> </li> <li> <p>Exercise capacity (e.g. the Six‐Minute Walk Distance test (6MWD))</p> </li> <li> <p>Health‐related quality of life (e.g. St. George's Respiratory Questionnaire (SGRQ))</p> </li> </ol> </p> <p>Reporting in the study one or more of the outcomes listed here was not an inclusion criterion for this review. </p> </section> </section> </section> <section id="CD012406-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012406-sec-0031"> <h4 class="title">Electronic searches</h4> <p>We identified studies from the Cochrane Airways Trials Register, which is maintained by the Information Specialist for the Group. The Cochrane Airways Trials Register contains studies identified from the following sources. </p> <p> <ol id="CD012406-list-0003"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL), through the Cochrane Register of Studies Online (crso.cochrane.org). </p> </li> <li> <p>Weekly searches of MEDLINE Ovid SP 1946 to date.</p> </li> <li> <p>Weekly searches of Embase Ovid SP 1974 to date.</p> </li> <li> <p>Monthly searches of PsycINFO Ovid SP 1967 to date.</p> </li> <li> <p>Monthly searches of Cumulative Index to Nursing and Allied Health Literature (CINAHL) EBSCO 1937 to date. </p> </li> <li> <p>Monthly searches of Allied and Complementary Medicine (AMED) EBSCO.</p> </li> <li> <p>Handsearches of the proceedings of major respiratory conferences.</p> </li> </ol> </p> <p>Studies contained in the Cochrane Airways Trials Register are identified through search strategies based on the scope of Cochrane Airways. We have provided details of these strategies, as well as a list of handsearched conference proceedings, in <a href="./appendices#CD012406-sec-0126">Appendix 1</a>. See <a href="./appendices#CD012406-sec-0132">Appendix 2</a> for search terms used to identify studies for this review. </p> <p>We also conducted a search of the US National Institutes of Health Ongoing Trials Register, ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>), and the World Health Organization International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>). </p> <p>We searched all databases from their inception to January 2018 and imposed no restrictions on language of publication. </p> </section> <section id="CD012406-sec-0032"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all primary studies and review articles for additional references and searched relevant manufacturers' websites for study information. We searched PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a>) for errata or retractions from included studies published in full text and reported within the review the date this was done. </p> </section> </section> <section id="CD012406-sec-0033"> <h3 class="title" id="CD012406-sec-0033">Data collection and analysis</h3> <section id="CD012406-sec-0034"> <h4 class="title">Selection of studies</h4> <p>Two review authors (DE and LF) independently screened titles and abstracts for inclusion of all potential studies identified as a result of the search and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. We retrieved full‐text study reports/publications, and two review authors (CK and LF) independently screened the full texts, identified studies for inclusion, and identified and recorded reasons for exclusion of ineligible studies. We encountered no disagreements, so the need to consult a third review author (SS or SJM) did not arise. We identified and excluded duplicates and collated multiple reports of the same trial, so that each trial rather than each report was the unit of interest in the review. We recorded the selection process in detail in the PRISMA flow diagram and the <a href="./references#CD012406-sec-0148" title="">Characteristics of excluded studies</a> table (<a href="./references#CD012406-bbs2-0050" title="MoherD , LiberatiA , TetzlaffJ , AltmanD . Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097] ">Moher 2009</a>). </p> </section> <section id="CD012406-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form that was piloted on at least one study in the review to extract study characteristics and outcome data. One review author (LF) extracted the following characteristics from included studies. </p> <p> <ol id="CD012406-list-0004"> <li> <p>Methods: study design, total duration, details of 'run‐in' period, number of centres and their locations, settings, withdrawals, and dates the study was carried out. </p> </li> <li> <p>Participants: number, mean age and range, gender, bronchiectasis severity, diagnostic criteria, baseline lung function, smoking history, inclusion and exclusion criteria. </p> </li> <li> <p>Interventions and comparisons: intervention, comparison, concomitant medications, and excluded medications. </p> </li> <li> <p>Outcomes: primary and secondary outcomes reported and follow‐up time points.</p> </li> <li> <p>Notes: funding source and notable conflicts of interest of study authors.</p> </li> </ol> </p> <p>Two review authors (LF and NR) independently extracted outcome data from the included studies. When investigators did not report outcome data in a usable way, we noted this in the <a href="./references#CD012406-sec-0147" title="">Characteristics of included studies</a> table. We resolved disagreements by reaching consensus or by involving a third review author (SS or SJM). One review author (LF) transferred data into the Review Manager 5 file (<a href="./references#CD012406-bbs2-0054" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), and a second review author (SS) verified and validated the information. One review author (CK) spot‐checked study characteristics for accuracy against the trial reports. </p> </section> <section id="CD012406-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (NR and LF) independently assessed the risk of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012406-bbs2-0041" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), according to the domains below. We resolved disagreements by discussion or by consultation with another review author (SS or SJM). </p> <p> <ol id="CD012406-list-0005"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ol> </p> <p>We graded each potential source of bias as bringing high, low, or unclear risk, provided a quote from the study report, and recorded our judgement in the 'Risk of bias' table. We summarised risk of bias judgements across different studies for each of the domains listed and reported these in a 'Risk of bias summary table' and a 'Risk of bias graph'. We considered blinding separately for different key outcomes when necessary (e.g. for unblinded outcome assessment, risk of bias for all‐cause mortality may be very different than for a patient‐reported pain scale). When information on risk of bias was related to unpublished data or correspondence with a study author, we noted this in the 'Risk of bias' table. </p> <p>When considering treatment effects, we took into account the risk of bias for studies that contributed to that outcome. </p> <section id="CD012406-sec-0037"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to the previously published protocol and have reported deviations from it in the <a href="#CD012406-sec-0145">Differences between protocol and review</a> section. </p> </section> </section> <section id="CD012406-sec-0038"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as odds ratios (ORs) and continuous data as mean differences (MDs) or standardised mean differences (SMDs). We analysed hospitalisation and exacerbation rates as rate ratios when possible. We entered data as a scale with a consistent direction of effect. We undertook meta‐analyses only when these were meaningful (i.e. when treatments, participants, and the underlying clinical question were similar enough for pooling to make sense). We narratively described skewed data reported as medians and interquartile ranges, as well as data not suitable for meta‐analysis (e.g. data from mixed methods regression). Our review did not include trials with multiple intervention arms, but if future updates of the review should identify this type of trial, we will include only the intervention arms relevant to this review. When we combined two comparisons (e.g. drug A vs placebo and drug B vs placebo) in the same meta‐analysis, we halved the control group to avoid double‐counting. </p> </section> <section id="CD012406-sec-0039"> <h4 class="title">Unit of analysis issues</h4> <p>The study participant was the unit of analysis in all included studies. For exacerbation and admission rates, we focused on the number of events experienced by the participant during the trial. For cross‐over trials, we used only data from the first pre‐cross‐over phase to minimise potential bias from carry‐over effects. </p> </section> <section id="CD012406-sec-0040"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors to verify key study characteristics and to obtain missing numerical outcome data when possible (e.g. only abstract available). When this was not possible and we thought that missing data might introduce serious bias, we explored the impact of including such studies in the overall assessment of results by performing a sensitivity analysis.  </p> </section> <section id="CD012406-sec-0041"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I<sup>2</sup> statistic to measure heterogeneity among the studies in each analysis. When we identified substantial heterogeneity (&gt; 50%), we reported this in the text and explored possible causes by conducting prespecified subgroup analyses (e.g. adults vs children).  </p> </section> <section id="CD012406-sec-0042"> <h4 class="title">Assessment of reporting biases</h4> <p>We were not able to pool more than 10 studies for any comparison; therefore, we were unable to explore small‐study effects and publication biases by using a funnel plot. </p> </section> <section id="CD012406-sec-0043"> <h4 class="title">Data synthesis</h4> <p>We included outcomes in meta‐analyses when we considered study designs, interventions, and outcomes as sufficiently similar. When we identified substantial heterogeneity (&gt; 50%), we reported outcomes in the text, revealing the direction and size of the effect, along with the strength of the evidence (risk of bias). Antibiotic studies varied by population, design, and outcomes. However, we identified few studies for each comparison, and estimates from a random‐effects model therefore may have been unreliable, we used a fixed‐effect model, reported data with 95% confidence intervals (CIs), and evaluated the impact of model choice by performing a sensitivity analysis, when appropriate. We synthesised and reported dichotomous and continuous data separately for each outcome (e.g. exacerbation/no exacerbation or exacerbation duration), and when study authors reported both end‐of‐study point estimates and change from baseline scores, we analysed these separately. </p> <section id="CD012406-sec-0044"> <h5 class="title">'Summary of findings' tables</h5> <p>We created 'Summary of findings' tables by using the following primary and secondary outcomes: exacerbations, hospitalisations, serious adverse events, deaths, and quality of life. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of evidence from studies contributing data to meta‐analyses for these outcomes. We used methods and recommendations as described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012406-bbs2-0041" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), and we used GRADEproGDT software (<a href="./references#CD012406-bbs2-0037" title="McMaster University (developed by Evidence Prime). GRADEproGDT. Version accessed 14 July 2016. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEproGDT</a>). We justified all decisions to downgrade or upgrade the quality of evidence provided by studies by using footnotes and adding comments to aid understanding when necessary. </p> </section> </section> <section id="CD012406-sec-0045"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out the following subgroup analyses, although data were insufficient for comparisons of all subgroups. However, we chose to present the data for different macrolides as subgroups for all outcomes. </p> <p> <ol id="CD012406-list-0006"> <li> <p>Macrolides versus other classes of long‐term antibiotics.</p> </li> <li> <p>Types of macrolides.</p> </li> <li> <p>Dose and frequency.</p> </li> <li> <p>Duration.</p> </li> </ol> </p> <p>We planned to use the following outcomes in conducting subgroup analyses.</p> <p> <ol id="CD012406-list-0007"> <li> <p>Exacerbations.</p> </li> <li> <p>Hospitalisations.</p> </li> <li> <p>Serious adverse events.</p> </li> </ol> </p> <p>We used the formal test for subgroup interactions provided in Review Manager 5 (<a href="./references#CD012406-bbs2-0054" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> <section id="CD012406-sec-0046"> <h4 class="title">Sensitivity analysis</h4> <p>We evaluated effects of methodological study quality by removing studies at high or unclear risk of bias for the domains of random sequence generation and allocation concealment. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012406-sec-0047" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012406-sec-0047"></div> <section id="CD012406-sec-0048"> <h3 class="title">Description of studies</h3> <section id="CD012406-sec-0049"> <h4 class="title">Results of the search</h4> <p>A systematic search, conducted on 18 January 2018, identified 103 unique records of potentially relevant trials. Of these, we considered 63 records irrelevant following inspection of their titles and abstracts. We obtained and read full texts for the remaining 40 records and formally excluded eight records (documented in <a href="./references#CD012406-bbs1-0002" title="">Excluded studies</a>). We contacted the authors of one study (two records) awaiting classification (see <a href="./references#CD012406-bbs1-0003" title="">Studies awaiting classification</a>). A total of 15 trials, with 30 records, met our inclusion criteria for studies of macrolides for bronchiectasis. We have summarised the selection process in the study flow diagram (<a href="#CD012406-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD012406-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012406-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012406-sec-0050"> <h4 class="title">Included studies</h4> <p>In 11 trials (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0007" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases2012;35(11):824‐7. [PUBMED: 23290037] ">Liu 2012</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>), study participants were adults, and in the remaining four trials (<a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>; <a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>; <a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a>), participants were children. See <a href="./references#CD012406-sec-0147" title="">Characteristics of included studies</a> for further details. See <a href="#CD012406-tbl-0005">Table 1</a> for an overview of study characteristics. </p> <div class="table" id="CD012406-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adults/</b> </p> <p><b>Children</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of macrolide</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Macrolide dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Delivery mode</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Combined weekly dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration (months unless stated)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Altenburg 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1750 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asintam 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cymbala 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 days per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diego 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 days per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>750 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Juthong 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Koh 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liu 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin, ambroxol hydrochloride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1050 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ambroxol hydrochloride (no intervention)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liu 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1050 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lourdesamy 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Masekela 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 mg for children weighing &lt; 15 kg and 250 mg ≥ 15 kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>875 mg for children weighing &lt; 15 kg and 1750 mg ≥ 15 kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sadigov 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 days per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serisier 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Valery 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 mg/kg up to a maximum of 600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Once a week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 mg/kg up to a maximum of 600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wong 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 days per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yalcin 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clarithromycin, supportive therapies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Supportive therapies (no intervention)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> </tbody> </table> </div> <section id="CD012406-sec-0051"> <h5 class="title">Methods</h5> <p>Fourteen of the 15 included studies were parallel‐group RCTs, and the remaining study was an RCT with a cross‐over design (<a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>). Nine trials were double‐blind, five were open‐label, and one did not report information on study blinding. The intervention duration ranged from eight weeks in <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a> to 24 months in <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>. The percentage of participants who withdrew after randomisation ranged from 0 in <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>and <a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a> to 27% in <a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>, with an average withdrawal proportion of 8.7% across all included studies. </p> <p>Seven trials were conducted in Asia (<a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>; <a href="./references#CD012406-bbs2-0007" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases2012;35(11):824‐7. [PUBMED: 23290037] ">Liu 2012</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>); three in Australia/New Zealand (<a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>); three in Europe (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a>); one in South Africa (<a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>); and one in the USA (<a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>). Please see <a href="#CD012406-fig-0002">Figure 2</a> for the global distribution of trials. The oldest study concluded in 1996 (<a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>), and the most recent in 2013 (<a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>). Three studies recruited participants through multiple centres (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>); the remainder were conducted at single centres (<a href="#CD012406-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD012406-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Global distribution of studies." data-id="CD012406-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Global distribution of studies.</p> </div> </div> </div> <p>Six trials used intention‐to‐treat analyses (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>; <a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a>), and seven trials included in analyses only participants who completed the study (<a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>; <a href="./references#CD012406-bbs2-0007" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases2012;35(11):824‐7. [PUBMED: 23290037] ">Liu 2012</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>); the analyses performed in two studies were unclear (<a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>). Nine studies reported power calculations for sample size estimation (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>), and all six remaining studies reported statistically significant results (<a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>; <a href="./references#CD012406-bbs2-0007" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases2012;35(11):824‐7. [PUBMED: 23290037] ">Liu 2012</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>; <a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>; <a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a>). </p> <p><b>Note:</b><i>We could not include results from</i><a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a><i>in the review, as data from the pre‐cross‐over phase alone were not available owing to ineffective randomisation procedures. See</i><a href="./references#CD012406-sec-0147" title="">Characteristics of included studies</a><i>and the associated risk of bias table for additional details.</i> </p> </section> <section id="CD012406-sec-0052"> <h5 class="title">Participants</h5> <p>We chose to present separately data from adults and children and data on different macrolides. </p> <section id="CD012406-sec-0053"> <h6 class="title">Adults</h6> <p>Eleven studies included a total of 690 adults aged 18 years and older, with a diagnosis of bronchiectasis confirmed by high‐resolution computed tomography (HRCT). Three studies specified the following numbers of exacerbations in the preceding year as screening criteria: at least three (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>); two (<a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>); and one (<a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). The number of randomised participants in each study ranged from 12 in <a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a> to 141 in <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>, with a mean age range of 48 years in <a href="./references#CD012406-bbs2-0007" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases2012;35(11):824‐7. [PUBMED: 23290037] ">Liu 2012</a> to 70.8 years in <a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>, although one study did not report this information (<a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>). Data on gender were missing for 81 randomised participants: Three trials reported gender distribution only for those who completed the study (<a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>), and one did not report gender (<a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>). Of 601 participants for whom data were available, 373 were female and 236 were male, with the percentage of male participants ranging from 23% in <a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a> to 54% in <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>, across individual studies. </p> <p>Three studies reported baseline disease severity in terms of Bhalla score: 9.5 (<a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>), 12.5 (<a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>), and 26.5 (<a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>). Seven studies reported baseline FEV<sub>1</sub> % predicted ranging from moderate impairment at 57% of predicted (<a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>), to mild impairment at 80.7% of predicted (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>), and two further studies reported baseline FEV<sub>1</sub> as 1.08 L in <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a> and 1.42 L in <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>. The remaining two studies did not report baseline lung function (<a href="./references#CD012406-bbs2-0007" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases2012;35(11):824‐7. [PUBMED: 23290037] ">Liu 2012</a>; <a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>). Seven studies reported smoking status, with the proportion of current smokers ranging from none in <a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a> and <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a> to 28% in <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a> one study reported 66% current or ex‐smokers (<a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>), and four studies did not report this information (<a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0007" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases2012;35(11):824‐7. [PUBMED: 23290037] ">Liu 2012</a>; <a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). </p> </section> <section id="CD012406-sec-0054"> <h6 class="title">Children</h6> <p>Four studies included a total of 190 randomised children, consisting of 81 girls and 98 boys (gender of participants lost to follow‐up was not reported in <a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>), younger than 18 years of age (<a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>; <a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>; <a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a>). Four studies reported a diagnosis of bronchiectasis by HRCT, and <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a> included children with chronic suppurative lung disease, thus meeting clinical criteria when HRCT was not available. Sample sizes ranged from 25 in <a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a> to 89 children in <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>, with mean age ranging from four years in <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a> to 13 years in <a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>. Participants in <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a> were indigenous children from Australia and New Zealand. Children in <a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a> had confirmed HIV infection, were receiving highly active antiretroviral therapy (HAART), and had undergone a sweat test to rule out cystic fibrosis. Children in <a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a> had increased airway responsiveness, confirmed by a metacholine challenge test. <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a> specified at least one exacerbation in the preceding year as one of its inclusion criteria. </p> <p>Three studies reported baseline FEV<sub>1</sub> % predicted as follows: 54.8% (<a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>), 76.5% (<a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a>), and 83% (<a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>). <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a> did not report lung function. </p> </section> </section> <section id="CD012406-sec-0055"> <h5 class="title">Interventions</h5> <section id="CD012406-sec-0056"> <h6 class="title">Adults</h6> <p>The 11 adult studies evaluated three types of oral macrolides. Six studies used azithromycin with doses ranging from 750 to 1750 mg per week for a period of 12 to 52 weeks, four studies used roxithromycin with doses ranging from 1050 to 2100 mg per week for 8 to 24 weeks, and one study used erythromycin at a dose of 3500 mg per week for 48 weeks. Seven studies compared the intervention with placebo (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>), three studies compared the intervention with no intervention (<a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>), and one study compared the intervention plus an antimucolytic with the antimucolytic alone (<a href="./references#CD012406-bbs2-0007" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases2012;35(11):824‐7. [PUBMED: 23290037] ">Liu 2012</a>). We have summarised in <a href="#CD012406-tbl-0005">Table 1</a> further details of interventions provided in individual studies. </p> <p><b>Note:</b> For all outcomes from <a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>, we have included only the mean change score, pending clarification by study authors of reported standard deviations. Therefore, we have included these data in the text narratively. </p> </section> </section> <section id="CD012406-sec-0057"> <h5 class="title">Outcomes</h5> <p>One study reported all of our prespecified outcomes (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>). </p> <p>Seven adult studies reported the frequency of exacerbations (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>; <a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>), and three reported the time to first exacerbation (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). Two children's studies reported the frequency of exacerbations (<a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>), and one also reported the time to first exacerbation and the duration of the exacerbation (<a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>). </p> <p>Two adult studies reported hospitalisations (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>), as did one paediatric study (<a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>). </p> <p>All three adult studies reported serious adverse events (<a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>), as did one study in which the participants were children (<a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>). </p> <p>Five of the adult studies reported sputum volume (<a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>), as did two paediatric studies (<a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>; <a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a>). Data from <a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a> were not usable (see note above). </p> <p>Nine adult studies reported lung function, measured as FEV<sub>1</sub> or forced vital capacity (FVC), or both (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>), as did all four paediatric studies (<a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>; <a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>; <a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a>). Data from <a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a> were not usable (see note above). </p> <p>Two adult studies reported FEV<sub>1</sub> before and after bronchodilation (<a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>), and one also reported FVC before and after bronchodilation (<a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). The remaining studies did not specify whether lung function was measured before or after bronchodilation. </p> <p>Three adult studies reported systemic markers such as C‐reactive protein (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>). </p> <p>Five adult studies reported adverse events (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>), as did two studies with children (<a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>). </p> <p>All 15 studies directly reported or inferred all‐cause mortality due to completion of the study period by all participants (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>; <a href="./references#CD012406-bbs2-0007" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases2012;35(11):824‐7. [PUBMED: 23290037] ">Liu 2012</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>; <a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>; <a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a>). </p> <p>Four adult studies reported the emergence of resistance to antibiotics (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>), as did one study that included children (<a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>). </p> <p>Two adult studies reported exercise capacity as measured by the 6MWD test (<a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). </p> <p>Nine adult studies reported health‐related quality of life using SGRQ (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0007" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases2012;35(11):824‐7. [PUBMED: 23290037] ">Liu 2012</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). </p> <p><b>Note:</b> Eight studies reported a formal sample size calculation (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>), but two of these studies did not recruit the target number of participants (<a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>). Six studies provided details of online trial registration (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). Eight studies included conflict of interest statements (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). Nine studies explicitly stated funding sources for the study (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>), but only six studies reported the role of funding sources in the trial (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). </p> </section> <section id="CD012406-sec-0058"> <h5 class="title">Subgroup analysis</h5> <p>One study with children conducted several post hoc subgroup analyses based on intervention compliance, intervention duration, bronchiectasis diagnosis, frequency of exacerbations at baseline, and positive bacterial infection at the beginning of the trial (<a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>). </p> </section> </section> <section id="CD012406-sec-0059"> <h4 class="title">Excluded studies</h4> <p>We excluded eight studies from this review. Six of these were not RCTs (<a href="./references#CD012406-bbs2-0017" title="KudoK , KomaseY , KowadaA , KabeJ . Preclinical and clinical studies on TE‐031 (A‐56268) in treatment of bacterial respiratory tract infections. Chemotherapy1988;36(Suppl 3):617‐22. ">Kudo 1988</a>; <a href="./references#CD012406-bbs2-0018" title="MinKY , KuriyamaT , FukudayY . Clinical evaluation of TE‐031 in the chronic respiratory infections [Japanese]. Japanese Pharmacology and Therapeutics1988;16(7):3027‐39. ">Min 1988</a>; <a href="./references#CD012406-bbs2-0019" title="MingO , YongL , ZhangW . Efficacy of macrolide and theophylline in the management of bronchiectasis. Respirology2005;10:A168. ">Ming 2005</a>; <a href="./references#CD012406-bbs2-0020" title="RikitomiN , ShishidoH , NagatakeT , MbakiU , MatsumotoK . Preclinical and clinical studies on TE‐031 (A‐56268) in treatment of bacterial respiratory tract infections. Chemotherapy1988;36(Suppl 3):715‐28. ">Rikitomi 1988</a>; <a href="./references#CD012406-bbs2-0021" title="SaitoA , ShimadaJ , OhmoriM , ShibaK , YamajiK , HojoT , et al. Clinical studies of TE‐031 (A‐56268). Chemotherapy1988;38:576‐85. ">Saito 1988</a>; <a href="./references#CD012406-bbs2-0023" title="UnouraT , MasudaM , TakeuchiK , ItohT , TamuraM , YukiT , et al. Clinical study on TE‐031(A‐56268) against respiratory infections. Physicians' Therapy Manual1988;36:544‐8. ">Unoura 1986</a>), one study was of less than four weeks' duration and therefore did not meet our inclusion criteria (<a href="./references#CD012406-bbs2-0022" title="TagayaE , TamaokiJ , KondoM , NagaiA . Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest2002;122(1):213‐8. [PUBMED: 12114361] ">Tagaya 2002</a>), and one study served as the protocol for a trial (<a href="./references#CD012406-bbs2-0016" title="ChangAB , GrimwoodK , WilsonAC , vanAsperenPP , ByrnesCA , O'GradyKA , et al. Bronchiectasis exacerbation study on azithromycin and amoxicillin‐clavulanate for respiratory exacerbations in children (BEST‐2): study protocol for a randomized controlled trial. Trials2013;14(53):14‐53. ">Chang 2013</a>). Please see <a href="./references#CD012406-sec-0148" title="">Characteristics of excluded studies</a> for additional details. </p> </section> </section> <section id="CD012406-sec-0060"> <h3 class="title">Risk of bias in included studies</h3> <p>Full details of the risk of bias judgements can be found in the 'Risk of bias' section at the end of each <a href="./references#CD012406-sec-0147" title="">Characteristics of included studies</a> table. <a href="#CD012406-fig-0003">Figure 3</a> and <a href="#CD012406-fig-0004">Figure 4</a> also provide a summary of the risk of bias in all included studies. Two independent review authors (LF and NR) independently assessed the risk of bias for each of the included studies and reached agreement. </p> <div class="figure" id="CD012406-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012406-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD012406-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012406-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012406-sec-0061"> <h4 class="title">Allocation</h4> <p>Review authors considered the methods used to generate randomisation sequences as low risk in six studies (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0007" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases2012;35(11):824‐7. [PUBMED: 23290037] ">Liu 2012</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a> and <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a> randomised participants using computer‐generated random numbers in a 1:1 ratio, and <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a> also reported using a block design. <a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a> described an independently performed computer‐generated random allocation sequence that used a permuted block size of 10. <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a> also used a computer‐generated random allocation sequence but with block sizes of 2, 4, and 8, and stratified patients by baseline sputum <i>Pseudomonas</i>. <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a> used a similar sequence generation with block size of 6 and stratified participants by centre. <a href="./references#CD012406-bbs2-0007" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases2012;35(11):824‐7. [PUBMED: 23290037] ">Liu 2012</a> randomised participants by using random number tables. The remaining nine studies provided unclear details regarding generation of the randomisation sequence (<a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>; <a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>; <a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>; <a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a>). </p> <p>We judged allocation concealment as having low risk of bias in four studies (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>), and we assigned unclear risk in 11 studies (<a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>; <a href="./references#CD012406-bbs2-0007" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases2012;35(11):824‐7. [PUBMED: 23290037] ">Liu 2012</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>; <a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>; <a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a>). <a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a> assigned identification codes with double‐blind allocation to treatment groups. <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a> used sequentially numbered, double‐sealed, opaque envelopes to conceal group allocation. <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a> used an independent trial pharmacist to dispense blinded study drug according to the randomisation sequence. <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a> randomly assigned participants to groups using a study‐independent statistician. Studies considered at unclear risk of allocation concealment bias did not provide adequate details of study methods to inform a clear judgement. </p> </section> <section id="CD012406-sec-0062"> <h4 class="title">Blinding</h4> <p>We judged performance of the trial to be at low risk of bias in six studies (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a> and <a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a> reported identical tablets in both groups. <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a><a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>, <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a><a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>, and <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a> stated that study personnel (patients, supervisors, staff, researchers, investigators) were blinded to treatment allocation at all times. We judged three studies as having high risk of performance bias, as they were open‐label trials (<a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0007" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases2012;35(11):824‐7. [PUBMED: 23290037] ">Liu 2012</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>). Investigators reported methods in the remaining studies in insufficient detail to permit a clear judgement of performance bias (<a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>; <a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>; <a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>; <a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a>). </p> <p>Six studies clearly stated blinding of outcome assessments (detection bias); we therefore judged these studies to be low risk of bias (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0007" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases2012;35(11):824‐7. [PUBMED: 23290037] ">Liu 2012</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). However, the remaining nine studies did not report methods in sufficient detail to inform a clear judgement of the risk of detection bias (<a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>; <a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>; <a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>; <a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a>). </p> </section> <section id="CD012406-sec-0063"> <h4 class="title">Incomplete outcome data</h4> <p>We judged incomplete outcome data (attrition bias) to introduce low risk of bias in nine studies (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>; <a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a>). Four studies reported no dropouts (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a>). Five studies clearly reported attrition rates and reasons for withdrawal (<a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). We judged the remaining six studies to have unclear risk of attrition bias owing to insufficient reporting (<a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0007" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases2012;35(11):824‐7. [PUBMED: 23290037] ">Liu 2012</a>; <a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>; <a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>). </p> </section> <section id="CD012406-sec-0064"> <h4 class="title">Selective reporting</h4> <p>We judged six of the included studies to have low risk of reporting bias (selective reporting) (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>), as the study protocols were available, and all outcomes of interest had been reported in the prespecified way. We judged the risk of reporting bias as unclear in nine studies (<a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>; <a href="./references#CD012406-bbs2-0007" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases2012;35(11):824‐7. [PUBMED: 23290037] ">Liu 2012</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>; <a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>; <a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>; <a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a>), as a full trial protocol was not available. </p> </section> <section id="CD012406-sec-0065"> <h4 class="title">Other potential sources of bias</h4> <p>We did not identify any other potential sources of bias in five studies (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>), but we could not adequately assess this in seven other included studies (<a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>; <a href="./references#CD012406-bbs2-0007" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases2012;35(11):824‐7. [PUBMED: 23290037] ">Liu 2012</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>; <a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>; <a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>). We judged three studies to have high risk of other potential sources of bias (<a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a><a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a>). Group allocation was ineffective in the pre‐cross‐over phase of <a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>, with eight of 11 participants receiving the intervention. In <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>, baseline sputum volume (primary outcome) was significantly higher in the intervention arm compared with the placebo group. Similarly, in <a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a>, baseline cytokine assay levels were again significantly higher in the intervention group compared with the placebo group. </p> </section> </section> <section id="CD012406-sec-0066"> <h3 class="title" id="CD012406-sec-0066">Effects of interventions</h3> <p>See: <a href="./full#CD012406-tbl-0001"><b>Summary of findings for the main comparison</b> Macrolides compared with placebo for adults with bronchiectasis</a>; <a href="./full#CD012406-tbl-0002"><b>Summary of findings 2</b> Macrolides compared with no intervention for adults with bronchiectasis</a>; <a href="./full#CD012406-tbl-0003"><b>Summary of findings 3</b> Macrolides compared with placebo for children with bronchiectasis</a>; <a href="./full#CD012406-tbl-0004"><b>Summary of findings 4</b> Macrolides compared with no intervention for children with bronchiectasis</a> </p> <section id="CD012406-sec-0067"> <h4 class="title">Macrolide versus placebo: adults</h4> <section id="CD012406-sec-0068"> <h5 class="title">Primary outcomes</h5> <section id="CD012406-sec-0069"> <h6 class="title">Exacerbations</h6> <p>Two adult studies of azithromycin ‐ <a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a> and <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a> ‐ and one adult study of erythromycin ‐ <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a> ‐ with a total of 341 participants were included in a meta‐analysis. Results show that macrolides reduced the frequency of exacerbations to a greater extent than placebo (OR 0.34, 95% CI 0.22 to 0.54; I<sup>2</sup> = 65%; <a href="./references#CD012406-fig-0006" title="">Analysis 1.1</a>; moderate‐quality evidence). This translates to 714 per 1000 in the placebo group experiencing one or more exacerbation compared with 459 per 1000 in the macrolide group (95% CI 355 to 574) or a number needed to treat for an additional beneficial outcome (NNTB) of 4 (95% CI 3 to 8) (<a href="#CD012406-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD012406-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Analysis 1.1. Cates plot showing the absolute reduction in numbers of participants experiencing one or more exacerbations in adults treated with macrolides compared with placebo (OR 0.34, 95% CI 0.22 to 0.54). 714 people per 1000 in the placebo group experienced one or more exacerbations compared with 459 (95% CI 355 to 574) per 1000 in the macrolide group." data-id="CD012406-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Analysis 1.1. Cates plot showing the absolute reduction in numbers of participants experiencing one or more exacerbations in adults treated with macrolides compared with placebo (OR 0.34, 95% CI 0.22 to 0.54). 714 people per 1000 in the placebo group experienced one or more exacerbations compared with 459 (95% CI 355 to 574) per 1000 in the macrolide group. </p> </div> </div> </div> <p>As heterogeneity was substantial, we tested the impact of a random‐effects model on the pooled effect size, which remained unchanged (OR 0.34, 95% CI 0.15 to 0.75). However, we noted significant differences between azithromycin and erythromycin subgroups (test for subgroup differences: Chi<sup>2</sup> = 5.63, df = 1 (P = 0.02), I<sup>2</sup> = 82.2%) and beneficial effects related to the two azithromycin studies (OR 0.23, 95% CI 0.13 to 0.40; I<sup>2</sup> = 0%) (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). Data show no differences between groups in the erythromycin study (OR 0.74, 95% CI 0.34 to 1.63). Two further studies did not report exacerbations in sufficient detail for inclusion in meta‐analyses. In one study of azithromycin (1500 mg/week for six months) involving 65 adults, trial authors reported that the intervention "significantly decreased the rate of event‐based exacerbations and significantly increased the time to the first event‐based exacerbation compared to placebo", but no further details were available (<a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>). In another study of roxithromycin involving 30 adults, two participants in the intervention group and one participant in the control group developed an exacerbation but researchers reported no further details (<a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>). </p> <p>Three adult studies reported significantly reduced incidence rate ratios in the intervention group as follows: 0.48 fewer exacerbations per year (95% CI 0.65 to 0.26) (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>); 0.57 fewer exacerbations per year (95% CI 0.77 to 0.42) (<a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>); and 0.38 fewer exacerbations per year (95% CI 0.54 to 0.25) (<a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). </p> <p>One adult study reported time to first exacerbation following a post hoc analysis, with a hazard ratio of 0.29 (95% CI 0.16 to 0.51) favouring azithromycin (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>). </p> </section> <section id="CD012406-sec-0070"> <h6 class="title">Hospitalisations</h6> <p>We included in a meta‐analysis two studies of azithromycin involving 151 adults (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>); results show no evidence of a reduction in hospitalisations in the azithromycin group compared with the placebo group (OR 0.56, 95% CI 0.19 to 1.62; I<sup>2</sup> = 0%; <a href="./references#CD012406-fig-0007" title="">Analysis 1.2</a>; low‐quality evidence), although these results should be interpreted with caution owing to the low event rate. </p> </section> <section id="CD012406-sec-0071"> <h6 class="title">Serious adverse events</h6> <p>Meta‐analysis included two studies of azithromycin involving 209 adults (<a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>), along with one study of erythromycin with 117 adults (<a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>). Serious adverse events included pneumonia, respiratory and non‐respiratory infections, haemoptysis, gastroenteritis, hernia, congestive heart failure, stroke, and skin carcinoma. Results show no difference in the numbers of participants with serious adverse events between study groups (OR 0.49, 95% CI 0.20 to 1.23; I<sup>2</sup> = 0%; <a href="./references#CD012406-fig-0008" title="">Analysis 1.3</a>; low‐quality evidence) and no evidence of subgroup differences between azithromycin and erythromycin (test for subgroup differences: Chi<sup>2</sup> = 0.48, df = 2 (P = 0.79), I<sup>2</sup> = 0%), although results should be interpreted with caution owing to low event rates. Removing the study with unclear risk of bias for allocation concealment ‐ <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a> ‐ from the meta‐analysis had little impact on the pooled treatment effect (OR 0.39, 95% CI 0.12 to 1.23; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD012406-sec-0072"> <h5 class="title">Secondary outcomes</h5> <section id="CD012406-sec-0073"> <h6 class="title">Sputum volume and purulence</h6> <p>One study of azithromycin (1000 mg/week for 12 weeks) with 78 adults reported no difference in sputum volume between study groups (MD 3.70, 95% CI ‐5.78 to 13.18; <a href="./references#CD012406-fig-0009" title="">Analysis 1.4</a>) (<a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>). One study of erythromycin (3500 mg/week for 48 weeks) with 117 adults reported a significant reduction in the change from baseline in 24‐hour sputum weight, favouring the intervention (median change ‐4.4 grams, interquartile ratio (IQR) ‐7.8 to ‐1; P = 0.01) (<a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>). One study of roxithromycin (2100 mg/week for 12 weeks) with 30 adults reported no improvement in sputum volume in either study group but provided no further details (<a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>). </p> </section> <section id="CD012406-sec-0074"> <h6 class="title">Measures of lung function</h6> <section id="CD012406-sec-0075"> <p><b>Forced expiratory volume in one second (FEV<sub>1</sub>)</b></p> <p>Seven adult studies reported FEV<sub>1</sub> as litres, percent of predicted, or both (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). One trial of azithromycin (1000 mg/week for 12 weeks) with 78 participants showed no evidence of benefit in FEV<sub>1</sub> % predicted from the intervention at the end of the study (MD 2.98, 95% CI ‐6.15 to 12.11; <a href="./references#CD012406-fig-0010" title="">Analysis 1.5</a>) (<a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>). One trial of azithromycin (1750 mg/week for 52 weeks<i>)</i> with 83 participants reported an increase of 1.03% in FEV<sub>1</sub> % predicted in the intervention group every three months compared with a decrease of 0.10% in the placebo group (P = 0.047) (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>). One trial of erythromycin (3500 mg/week for 48 weeks) with 117 participants reported a significant difference in FEV<sub>1</sub> %predicted change from baseline between groups, favouring macrolides (MD 2.40, 95% CI 0.34 to 4.46; <a href="./references#CD012406-fig-0011" title="">Analysis 1.6</a>) (<a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>). One study of azithromycin (1500 mg/week for 6 months) with 65 participants reported significant improvements in prebronchodilator and postbronchodilator FEV<sub>1</sub> but provided no further details (<a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>). One study of roxithromycin (2100 mg/week for 12 weeks) with 30 participants reported no improvement in either study group but provided no further details (<a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>). </p> <p>A meta‐analysis of data from two studies showed no benefit from azithromycin or roxithromycin in FEV<sub>1</sub> at the end of the study (MD 0.02 L, 95% CI ‐0.17 to 0.22; <a href="./references#CD012406-fig-0012" title="">Analysis 1.7</a>) (<a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>). Results show were no significant differences between the two macrolides (test for subgroup differences: Chi<sup>2</sup> = 0.43, df = 1 (P = 0.51), I<sup>2</sup> = 0%). Another study of azithromycin (1500 mg/week for 6 months) with 141 participants also showed no benefit from the intervention in change in FEV<sub>1</sub> during the study (MD 0.04 L, 95% CI ‐0.03 to 0.11; <a href="./references#CD012406-fig-0013" title="">Analysis 1.8</a>) (<a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). </p> </section> <section id="CD012406-sec-0076"> <p><b>Forced vital capacity (FVC)</b></p> <p>Four adult studies reported FVC as percent of predicted, in litres, or both ways (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). One trial of azithromycin (1000 mg/week for 12 weeks) with 78 participants showed no benefit from the intervention at the end of the study in terms of FVC % predicted (MD 1.07, 95% CI ‐9.27 to 11.41; <a href="./references#CD012406-fig-0014" title="">Analysis 1.9</a>) (<a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>). Another study of azithromycin (1750 mg/week for 52 weeks) with 83 participants reported an increase in FVC of 1.33% predicted in the intervention group and a decrease of 0.30% predicted in the placebo group every three months (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>). </p> <p>A meta‐analysis of data from two studies with 94 participants showed no benefit at the end of the study from azithromycin or roxithromycin in terms of FVC (MD 0.08 L, 95% CI ‐0.19 to 0.36; <a href="./references#CD012406-fig-0015" title="">Analysis 1.10</a>) (<a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>). Results show no significant differences between the two macrolides (test for subgroup differences: Chi<sup>2</sup> = 1.57, df = 1 (P = 0.21), I<sup>2</sup> = 36.3%). One study of azithromycin (1500 mg/week for six months) with 141 participants showed no benefit from the intervention in changes in FVC (MD 0.08 L, 95% CI ‐0.53 to 0.69; <a href="./references#CD012406-fig-0016" title="">Analysis 1.11</a>) (<a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). </p> </section> <section id="CD012406-sec-0077"> <p><b>FEV<sub>1</sub>/FVC ratio</b></p> <p>One study of azithromycin (1000 mg/week for 12 weeks) with 78 participants reported the FEV<sub>1</sub>/FVC ratio showing no evidence of benefit from the intervention at the end of the study (MD 3.57, 95% CI ‐3.89 to 11.03; <a href="./references#CD012406-fig-0017" title="">Analysis 1.12</a>) (<a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>). </p> </section> </section> <section id="CD012406-sec-0078"> <h6 class="title">Systemic markers of infection</h6> <p>One trial of azithromycin (1750 mg/week for 52 weeks) with 83 participants reported no significant differences between median CRP values at the end of the study (azithromycin 2.6 mg/dL, IQR 1.5 ‐ 7; control 3.9 mg/dL, IQR 2 ‐ 6.15) and no changes in serum levels, although P values were not reported (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>). Similarly, one trial of erythromycin (3500 mg/week for 48 weeks) with 117 participants reported no differences between groups in CRP levels (median change difference ‐0.2 mg/L, IQR ‐1.5 to 1.2), although again significance values were not reported (<a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>). </p> </section> <section id="CD012406-sec-0079"> <h6 class="title">Adverse events</h6> <p>Five studies of three different macrolides (azithromycin, erythromycin, and roxithromycin) with 435 adult participants were included in a meta‐analysis (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>), showing no differences between study groups in the numbers of people experiencing adverse events (OR 0.83, 95% CI 0.51 to 1.35; I<sup>2</sup> = 28%; <a href="./references#CD012406-fig-0018" title="">Analysis 1.13</a>). Trials provided no evidence of differences between the three different macrolides (test for subgroup differences: Chi<sup>2</sup> = 2.07, df = 2 (P = 0.36), I<sup>2</sup> = 3.3%). Removing two studies from the analysis with unclear risk of bias for sequence generation or allocation concealment had little impact on the pooled treatment effect (OR 0.83, 95% CI 0.50 to 1.39; I<sup>2</sup> = 27%) (<a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>). </p> </section> <section id="CD012406-sec-0080"> <h6 class="title">All‐cause mortality</h6> <p>Data show no deaths during the intervention period in six of the adult studies (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). One study of azithromycin (1000 mg/week for 12 weeks) with 78 participants reported no deaths in the placebo group and two deaths in the intervention group attributed to bronchopneumonia and not considered treatment‐related (<a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>). In performing our GRADE assessment, we judged this outcome to be of low quality (<a href="./full#CD012406-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD012406-sec-0081"> <h6 class="title">Emergence of resistance to antibiotics</h6> <p>One study of azithromycin with 83 adults reported no differences between groups in the emergence of resistance to antibiotics (OR 0.71, 95% CI 0.30 to 1.69; <a href="./references#CD012406-fig-0019" title="">Analysis 1.14</a>) (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>). In another study of roxithromycin (2100 mg/week for 8 weeks) with 26 adults, none of the participants experienced antibiotic resistance to any bacterial strain (<a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>). However, a study of erythromycin (3500 mg/week for 48 weeks) with 117 participants reported a higher proportion of macrolide‐resistant oropharyngeal streptococci in the intervention group compared with the placebo group (median change difference 25.5%, IQR 15% to 33.7%; P = 0.001) (<a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>). </p> </section> <section id="CD012406-sec-0082"> <h6 class="title">Exercise capacity</h6> <p>One study of erythromycin (3500 mg/week for 48 weeks) with 117 adults reported no differences in the change in 6MWD between study groups (MD ‐6.30, 95% CI ‐28.86 to 16.26; <a href="./references#CD012406-fig-0020" title="">Analysis 1.15</a>) (<a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>). Similarly, a study of azithromycin (1500 mg/week for 6 months) with 141 adults reported no significance difference in change in 6MWD between study groups (mean change difference 6.48 m, 95% CI ‐11.28 to 24.22; P = 0.4) (<a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). </p> </section> <section id="CD012406-sec-0083"> <h6 class="title">Health‐related quality of life</h6> <p>One study with 68 adults showed a significantly lower (better) SGRQ total score at the end of the study in the intervention group compared with the placebo group (MD ‐8.90, 95% CI ‐13.13 to ‐4.67; <a href="./references#CD012406-fig-0021" title="">Analysis 1.16</a>; moderate‐quality evidence) and an MD that exceeded the 4‐unit threshold of clinical significance (<a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>). We included in a meta‐analysis four adult studies with 305 participants showing greater improvements from baseline to study endpoint in quality of life with macrolides (MD ‐2.86, 95% CI ‐5.67 to ‐0.04; <a href="./references#CD012406-fig-0022" title="">Analysis 1.17</a>; low‐quality evidence) (<a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). Although data show no significant differences between azithromycin and roxithromycin (test for subgroup differences: Chi<sup>2</sup> = 0.01, df = 1 (P = 0.92), I<sup>2</sup> = 0%), the beneficial effect was largely observed in the azithromycin group. Differences between groups in all four studies were below the threshold of clinical significance. Removing from the meta‐analysis the two studies with unclear risk of bias for sequence generation and allocation concealment had no impact on the pooled treatment effect (MD ‐2.97, 95% CI ‐5.94 to ‐0.00; I<sup>2</sup> = 0%) (<a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>). </p> <p>One study of azithromycin (1750 mg/week for 52 weeks) with 83 participants reported a significant improvement in quality of life (SGRQ total) with the intervention compared with placebo (intervention group mean change ‐6.09, control group mean change ‐2.06; P = 0.05) (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>). </p> </section> </section> </section> <section id="CD012406-sec-0084"> <h4 class="title">Macrolide versus no intervention: adults</h4> <section id="CD012406-sec-0085"> <h5 class="title">Primary outcomes</h5> <section id="CD012406-sec-0086"> <h6 class="title">Exacerbations</h6> <p>One study of roxithromycin with 43 adults (1050 mg/week 6 months) did not find a clear difference in the frequency of exacerbations between groups (OR 0.31, 95% CI 0.08 to 1.15; <a href="./references#CD012406-fig-0023" title="">Analysis 2.1</a>; moderate‐quality evidence; <a href="./full#CD012406-tbl-0002">summary of findings Table 2</a>) (<a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>). </p> <p>None of the included studies reported our other primary outcomes: hospitalisation and adverse or serious adverse events. </p> </section> </section> <section id="CD012406-sec-0087"> <h5 class="title">Secondary outcomes</h5> <section id="CD012406-sec-0088"> <h6 class="title">Sputum volume and purulence</h6> <p>One study of azithromycin with 30 adults (750 mg/week 3 months) reported a decrease in sputum volume with macrolides (MD ‐11.00 mL/d; P &lt; 0.05) (<a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>). Following the intervention, sputum volume decreased by 8.9 mL/d in the azithromycin group and increased by 2.1 mL/d in the control group by three months. Data show no differences in changes in sputum purulence scores between groups (mean change score: azithromycin 0.8, control 0.7) by three months. </p> </section> <section id="CD012406-sec-0089"> <h6 class="title">Measures of lung function</h6> <p>One study of azithromycin with 30 adults (750 mg/week 3 months) found no differences between groups in FEV<sub>1</sub> or FVC (<a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>). Relative to baseline, FEV<sub>1</sub> increased by 0.06 L and 0.04 L in azithromycin and control groups, respectively, and FVC decreased by 0.07 L and 0.08 L in azithromycin and control groups, respectively, by three months. </p> </section> <section id="CD012406-sec-0090"> <h6 class="title">Systemic markers of infection</h6> <p>One study of azithromycin with 30 adults (750 mg/week 3 months) found no differences between groups in CRP levels (<a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>). This study reported a reduction in CRP levels by three months compared with baseline in both groups: mean reduction: ‐17 in the azithromycin group, ‐11 in the control group. </p> </section> <section id="CD012406-sec-0091"> <h6 class="title">Adverse events</h6> <p>One adult study reported adverse events as event rates but did not report the number of participants experiencing at least one adverse event (<a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>). </p> </section> <section id="CD012406-sec-0092"> <h6 class="title">Mortality</h6> <p>Two adult studies reported no deaths during the study (<a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>). Through GRADE assessment, we judged this outcome to be of very low quality (<a href="./full#CD012406-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD012406-sec-0093"> <h6 class="title">Quality of life</h6> <p>Two roxithromycin studies with 89 adults (1050 mg/week 6 months) reported significantly better quality of life with macrolides compared with no intervention at the end of six months (MD ‐8.81, 95% CI ‐14.33 to ‐3.28; <a href="./references#CD012406-fig-0024" title="">Analysis 2.2</a>; moderate‐quality evidence) (<a href="./references#CD012406-bbs2-0007" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases2012;35(11):824‐7. [PUBMED: 23290037] ">Liu 2012</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>). One study of azithromycin with 30 adults (750 mg/week for 3 months) reported a significant improvement in quality of life, measured by the SGRQ total score, after three months compared with no intervention (MD ‐12.00; P &lt; 0.05; low‐quality evidence) (<a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>). The total score decreased by 7.9 units in the azithromycin group and increased by 4.1 units in the control group. It was not considered appropriate to combine these outcomes in a meta‐analysis owing to differences in macrolides, doses, and study duration. </p> <p>The included studies did not report our other secondary outcomes ‐ exercise capacity and resistance to antibiotics. </p> </section> </section> </section> <section id="CD012406-sec-0094"> <h4 class="title">Macrolide versus placebo: children</h4> <section id="CD012406-sec-0095"> <h5 class="title">Primary outcomes</h5> <section id="CD012406-sec-0096"> <h6 class="title">Exacerbations</h6> <p>Two studies reported exacerbation frequency in children. One study of azithromycin (30 kg/week for up to 24 months) reported that in children, exacerbation frequency was reduced more with macrolides than with placebo (IRR 0.50, 95% CI 0.35 to 0.71; 89 children; one study; low‐quality evidence). However, we feel this should be interpreted with a degree of caution as the same study reported no significant benefit from the intervention in the number of children with at least one exacerbation (OR 0.40, 95% CI 0.11 to 1.41; low‐quality evidence) nor in the time to first exacerbation (hazard ratio 0·63, 95% CI 0·40–1·00; log‐rank P = 0.12) (<a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>). Another study of erythromycin (875 &lt; 15 kg &gt; 1750 mg/week for 52 weeks) in 42 children reported that three children in the intervention group remained exacerbation‐free during the study, and all children in the placebo group had at least one exacerbation (<a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>). </p> </section> <section id="CD012406-sec-0097"> <h6 class="title">Hospitalisations</h6> <p>One study of azithromycin with 89 children showed no evidence of a reduction in numbers of children hospitalised for exacerbations between study groups (OR 0.28, 95% CI 0.07 to 1.11; <a href="./references#CD012406-fig-0025" title="">Analysis 3.1</a>; low‐quality evidence), although again these results should be interpreted with caution owing to the low event rate (<a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>). </p> </section> <section id="CD012406-sec-0098"> <h6 class="title">Serious adverse events</h6> <p>One study of azithromycin with 89 children reported serious adverse events (<a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>), showing no differences between groups in the number of children experiencing at least one event (OR 0.43, 95% CI 0.17 to 1.05; <a href="./references#CD012406-fig-0026" title="">Analysis 3.2</a>; low‐quality evidence). The majority of the serious adverse events related either to an exacerbation or an investigation related to bronchiectasis (e.g., bronchoscopy). </p> </section> </section> <section id="CD012406-sec-0099"> <h5 class="title">Secondary outcomes</h5> <section id="CD012406-sec-0100"> <h6 class="title">Sputum volume and purulence</h6> <p>One study of roxithromycin with 25 children reported a reduction in sputum purulence score with the intervention (MD ‐0.78, 95% CI ‐1.32 to ‐0.24; <a href="./references#CD012406-fig-0027" title="">Analysis 3.3</a>) (<a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>). </p> </section> <section id="CD012406-sec-0101"> <h6 class="title">Measures of lung function</h6> <section id="CD012406-sec-0102"> <p><b>Forced expiratory volume in one second (FEV<sub>1</sub>)</b></p> <p>A meta‐analysis of two studies with 65 participants showed no evidence of benefit from azithromycin or roxithromycin in FEV<sub>1</sub> expressed as percent of predicted by the end of the study (MD 1.73, 95% CI ‐3.32 to 6.78; <a href="./references#CD012406-fig-0028" title="">Analysis 3.4</a>) (<a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>). Removing the study, which had unclear risk of bias for sequence generation and allocation concealment from the meta‐analysis, had little impact on the treatment effect (MD 3.70, 95% CI ‐5.99 to 13.39) (<a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>). Another study of erythromycin (875 &lt; 15 kg &gt; 1750 mg/week for 52 weeks) with 42 children who had HIV and were all receiving highly active antiretroviral therapy (HAART) reported no difference in FEV<sub>1</sub> % predicted between groups at the end of the study (MD 5.50, 95% CI ‐7.26 to 18.26) (<a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>). </p> </section> <section id="CD012406-sec-0103"> <p><b>Forced vital capacity (FVC)</b></p> <p><a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a> reported no significant difference in FVC % predicted between groups at the end of the study (MD 5.00, 95% CI ‐5.61 to 15.61). </p> </section> </section> <section id="CD012406-sec-0104"> <h6 class="title">Systemic markers of infection</h6> <p>One erythromycin study (875 mg &lt; 15 kg &gt; 1750 mg/week for 52 weeks) of 42 children with HIV who were receiving HAART reported no differences in CRP levels between groups (MD 1.60, 95% CI ‐38.38 to 41.58) (<a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>). </p> </section> <section id="CD012406-sec-0105"> <h6 class="title">Adverse events</h6> <p>One study of azithromycin (30 mg/kg/week for 24 months) in 89 participants reported no differences between study groups in the numbers of children experiencing adverse events (OR 0.78, 95% CI 0.33 to 1.83; <a href="./references#CD012406-fig-0029" title="">Analysis 3.5</a>) (<a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>). </p> </section> <section id="CD012406-sec-0106"> <h6 class="title">All‐cause mortality</h6> <p><a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a> reported the death of one randomised participant but did not state the study group to which that participant had been assigned (low‐quality evidence). </p> </section> <section id="CD012406-sec-0107"> <h6 class="title">Emergence of resistance to antibiotics</h6> <p>One study of azithromycin in 89 children reported an increase in macrolide‐resistant bacteria (OR 7.13, 95% CI 2.13 to 23.79; <a href="./references#CD012406-fig-0030" title="">Analysis 3.6</a>), an increase in resistance to <i>Streptococcus pneumoniae</i> (OR 13.20, 95% CI 1.61 to 108.19; <a href="./references#CD012406-fig-0031" title="">Analysis 3.7</a>), and an increase in resistance to <i>Staphylococcus aureus</i> (OR 4.16, 95% CI 1.06 to 16.32; <a href="./references#CD012406-fig-0032" title="">Analysis 3.8</a>) with macrolides compared with placebo (<a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>). </p> <p>The included studies did not report our other secondary outcomes: exercise capacity and health‐related quality of life. </p> </section> </section> </section> <section id="CD012406-sec-0108"> <h4 class="title">Macrolide versus no intervention: children</h4> <section id="CD012406-sec-0109"> <h5 class="title">Primary outcomes</h5> <p>The included study did not report our primary outcomes: exacerbations, hospitalisations, and adverse and serious adverse events. </p> </section> <section id="CD012406-sec-0110"> <h5 class="title">Secondary outcomes</h5> <section id="CD012406-sec-0111"> <h6 class="title">Sputum volume and purulence</h6> <p>One study of clarithromycin with 34 children (105 mg/week 3 months) reported a significantly greater reduction in sputum volume with macrolides compared with placebo (P = 0.0001) but did not report exact values for each group (<a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a>). </p> </section> <section id="CD012406-sec-0112"> <h6 class="title">Measures of lung function</h6> <p><a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a> also reported no differences in FEV<sub>1</sub> between groups but did not report exact values and significance levels. </p> </section> <section id="CD012406-sec-0113"> <h6 class="title">Mortality</h6> <p><a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a> reported no deaths (low‐quality evidence). </p> <p>The included study did not report our other secondary outcomes: systemic markers of infection, adverse events, resistance to antibiotics, exercise capacity, and quality of life. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012406-sec-0114" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012406-sec-0114"></div> <section id="CD012406-sec-0115"> <h3 class="title" id="CD012406-sec-0115">Summary of main results</h3> <p>Fifteen randomised trials met the inclusion criteria for this systematic review; 11 studies included adult participants only (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0003" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0007" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases2012;35(11):824‐7. [PUBMED: 23290037] ">Liu 2012</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>), and in four studies (<a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>; <a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a>; <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>; <a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a>), the participants were children. Considerable clinical heterogeneity was evident on a range of other factors, including four different types of macrolides, doses ranging from 750 mg/week to 3500 mg/week with regimens varying from twice daily to once a week, intervention duration ranging from eight weeks to 24 months, and background therapies administered to all groups in two studies. None of the included studies compared one type of macrolide versus another or versus a non‐macrolide antibiotic. </p> <p>Evidence shows a reduction in exacerbations seen in our aggregation of data from four adult studies, including <a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>, <a href="./references#CD012406-bbs2-0011" title="SadigovAS , MammadovGT . Azythromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis: how we can improve the clinical features of severe disease?. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A3512. ">Sadigov 2013</a><a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a> and <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>, and from one study of children ‐ <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a> ‐ comparing macrolides with placebo, and we used GRADE criteria to assess the quality of this evidence as moderate. Most of these studies (with the exception of <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>) used azithromycin. <a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a> reported no reduction in the number of exacerbations over 52 weeks with erythromycin compared with placebo. This study was carried out in South African children with HIV who were receiving antiretrovirals and showed varying degrees of HIV virological suppression. The specifics of this population make it difficult to generalise the findings of <a href="./references#CD012406-bbs2-0010" title="MasekelaR , AndersonR , GongxekaH , SteelHC , GreenRJ . Lack of efficacy of erythromycin in children with human immunodeficiency virus‐related bronchiectasis – a randomised controlled trial. Paediatric Respiratory Reviews. 2013; Vol. 14, issue 2:S82/A009‐12. [DOI: http://dx.doi.org/10.1016/S1526‐0542(13)70150‐7] MasekelaR , AndersonR , GongxekaH , SteelHC , et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV‐related bronchiectasis: a randomised, placebo‐controlled trial. Journal of Antivirals and Antiretrovirals2013;5:44‐9. ">Masekela 2013</a> to individuals with bronchiectasis in less specialised circumstances. Studies comparing macrolides with no intervention were insufficient to establish clear effects. For hospitalisations, data show no evidence of benefit with azithromycin based on aggregation of data from two adult studies (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>), along with one study of children (<a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>), and on evidence of low quality. We are unable to draw any conclusions on which macrolides may be most beneficial, as data were not available for all of our planned subgroups. Available low‐quality evidence from four adult studies, including <a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a><a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a><a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a> and <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>, and from one study of children ‐ <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a> ‐ suggests that participants receiving macrolides experienced more adverse events. We are again unable to draw clear conclusions regarding the effectiveness of different macrolides, as four of the five studies used azithromycin. Studies comparing macrolides with no intervention did not report this outcome. </p> <p>Overall our review provides promising, but inconclusive, results for our three predefined primary outcomes, but on the basis of currently available evidence, we are unable to present robust conclusions. </p> <p>For our secondary outcomes, aggregated data from six studies comparing macrolides against placebo and yielding moderate‐ to low‐quality evidence (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0002" title="AsintamP , KiranantawatN , JuthongS . Can roxithromycin improve quality of life in bronchiectatic patients?. European Respiratory Journal. 2012; Vol. 40:P2168. ">Asintam 2012</a>; <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>; <a href="./references#CD012406-bbs2-0009" title="Lourdesamy AnthonyAI , MuthukumaruU . Efficacy of azithromycin in the treatment of bronchiectasis. Respirology (Carlton, Vic.)2014;19(8):1178‐82. [PUBMED: 25183304] ">Lourdesamy 2014</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>) indicate that macrolides have a positive impact on health‐related quality of life, as measured by St. George's Respiratory Questionnaire (SGRQ). Similarly, three studies comparing macrolides with no treatment showed improved quality of life with the intervention (<a href="./references#CD012406-bbs2-0004" title="DiegoAD , MilaraJ , Martinez‐MoragónE , PalopM , LeónM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis. Respirology2013;18(7):1056‐62. ">Diego 2013</a>; <a href="./references#CD012406-bbs2-0007" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases2012;35(11):824‐7. [PUBMED: 23290037] ">Liu 2012</a>; <a href="./references#CD012406-bbs2-0008" title="LiuJ , ZhongX , HeZ , WeiL , ZhengX , ZhangJ , et al. Effect of low‐dose, long‐term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators of Inflammation2014;2014:708608. [PUBMED: 25580060] ">Liu 2014</a>). Data on sputum volume and purulence, measures of lung function, markers of infection, and demonstrated exercise capacity provided no indication of benefit from macrolides in adults. One of the largest adult studies of erythromycin provided limited evidence of increased resistance to macrolides (<a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>). </p> <p>None of the four children's studies measured quality of life. Macrolides were associated with improved sputum characteristics in two children's studies (<a href="./references#CD012406-bbs2-0006" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. [PUBMED: 9163637] ">Koh 1997</a>; <a href="./references#CD012406-bbs2-0015" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. [PUBMED: 16476120] ">Yalcin 2006</a>). Studies with children provided no evidence of benefit from macrolides in terms of measures of lung function, markers of infection, or demonstrated exercise capacity. One study of azithromycin with children provided limited evidence of increased resistance to macrolides (<a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>). </p> <p>Evidence of moderate to very low quality from the 15 included studies provided no indication of a higher mortality rate with macrolides. </p> <p>In relation to our predefined secondary outcomes, health‐related quality of life data further strengthen the impression noted in our primary outcomes that this intervention merits further exploration in high‐quality clinical trials. </p> </section> <section id="CD012406-sec-0116"> <h3 class="title" id="CD012406-sec-0116">Overall completeness and applicability of evidence</h3> <p>We have identified studies of macrolides in bronchiectasis reporting exacerbation and hospitalisation rates. Data for planned secondary outcomes, particularly adverse effects, are lacking. Our findings are based on studies totalling 690 adults and 190 children. Investigators used several different macrolide antibiotics (azithromycin, erythromycin, roxithromycin, and clarithromycin) in these populations in a variety of international settings. This breadth enhances the generalisability of findings but may conceal an advantage of, for example, one macrolide over another or use in adults over use in children, as none of the included studies reported direct comparisons between different macrolides or between adults and children. Small and short‐term studies mean that we may not detect small but clinically important increases in absolute risk for serious adverse events. Such adverse events, including mortality as reported in <a href="./references#CD012406-bbs2-0053" title="RayWA , MurrayKT , HallK , ArbogastPG , SteinCM . Azithromycin and the risk of cardiovascular death. New England Journal of Medicine2012;366:1881‐90. ">Ray 2012</a> and hearing loss as described in <a href="./references#CD012406-bbs2-0025" title="AlbertRK , ConnettJ , BaileyWC , CasaburiR , CooperJAD , CrinerGJ , et al. Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine 2011, 2011;365(8):689‐98. ">Albert 2011</a>, have been reported in larger studies of macrolides for indications other than bronchiectasis. Although this review provides limited evidence of benefit associated with macrolide antibiotics, their relative benefit compared with benefit derived from other types of antibiotics remains unknown, as we did not identify any studies that included these comparisons. </p> <p>Apart from <a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>, <a href="./references#CD012406-bbs2-0005" title="JuthongS , EiamsaardS . The effects of roxithromycin as anti‐inflammatory agent on clinical outcomes in patient with bronchiectasis: a double blinded randomized controlled study. European Respiratory Journal. 2011; Vol. 38(Suppl 55):455s. ">Juthong 2011</a>, <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>, <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>, and <a href="./references#CD012406-bbs2-0013" title="HareKM , GrimwoodK , ChangAB , ChatfieldMD , ValeryPC , LeachAJ , et al. Nasopharyngeal carriage and macrolide resistance in indigenous children with bronchiectasis randomized to long‐term azithromycin or placebo. European Journal of Clinical Microbiology and Infectious Diseases2015;34(11):2275‐85. [PUBMED: 26363637] SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryP , et al. [Multicentre bronchiectasis study: an international observational and interventional study of bronchiectasis in indigenous children]. Respirology. 2008; Vol. 13(Suppl 2):A19. SingletonR , MorrisP , LeachA , RosebyR , WhiteA , ValeryPC , et al. BIS ‐ Multi‐centre bronchiectasis study: a collaborative and international study of bronchiectasis in indigenous children. Respirology2007; Vol. 12, issue 4:A‐192. ValeryPC , MorrisPS , ByrnesCA , GrimwoodK , TorzilloPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic‐fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1(8):610‐20. [PUBMED: 24461664] ">Valery 2013</a>, we found a lack of information on microbial resistance associated with the macrolides used in the reports of included studies. No studies were designed to evaluate changes in resistance patterns in the wider community. </p> </section> <section id="CD012406-sec-0117"> <h3 class="title" id="CD012406-sec-0117">Quality of the evidence</h3> <p>The overall quality of studies included in this review ranges from very low to moderate for outcomes included in the GRADE assessment. From adult studies comparing macrolides versus placebo, the evidence for frequency of exacerbations and mortality from all causes is of moderate quality owing to imprecision of the effect (limited to azithromycin). Evidence for hospitalisations, serious adverse events, and quality of life was of low quality owing to study design limitations (unclear study methods, open‐label approach) and imprecision of the effect (few studies and wide confidence intervals), which resulted in downgrading of the quality of outcomes. Evidence for all‐cause mortality is of poor quality owing to unclear reporting and losses to follow‐up. From adult studies that compared macrolides versus no intervention, the evidence for frequency of exacerbations and quality of life as assessed by the SGRQ is of moderate quality owing to limitations in study design (open‐label study) and imprecision of the effect (few studies and no confidence intervals). The quality of evidence for mortality from all causes is very low owing to serious design limitations (open‐label study, unclear study methods) and inadequate reporting of participants lost to follow‐up. </p> <p>Studies that compared macrolides versus placebo in children have provided low‐quality evidence on frequency of exacerbations, hospitalisations, serious adverse events, and mortality owing to design limitations (unclear methods), imprecision (wide confidence intervals and low event rates), and no information on participants lost to follow‐up. The single small study that compared macrolides versus no intervention in children provided low‐quality evidence on mortality from all causes owing to insufficient information on trial methods and imprecision. </p> <p>We judged only four of our 15 included studies ‐ three with adults and one with children ‐ as having low risk of bias across all domains. Selection bias was unclear in nearly half of the included studies owing to lack of detailed reporting on random sequence generation and allocation concealment. Most studies blinded participants to group allocation, but several studies described investigator blinding in a way that was unclear, and most trials reported blinding of outcome assessment that was also unclear. None of the included studies had high risk of attrition or reporting bias, although some studies provided no information on participants who were lost to follow‐up. Furthermore, only six studies explicitly reported the role of funders in the trial; six studies registered their protocol on trial registries; and eight studies reported that investigators performed a formal sample size calculation before the start of the trial. </p> </section> <section id="CD012406-sec-0118"> <h3 class="title" id="CD012406-sec-0118">Potential biases in the review process</h3> <p>We used a comprehensive systematic search, conducted by a highly experienced information specialist, to identify potentially eligible studies. We searched multiple resources, including electronic databases, journals, conference proceedings, reference lists of included studies, citations of included studies, and trial registries. Nevertheless, we recognise the possibility of publication bias in this review that could either overestimate or underestimate effects of the intervention in terms of the different outcomes included in the review. Trials showing no, or negative, effects are less likely to be offered for publication, and if offered are less likely to be accepted, resulting in a biased set of data available for review. As we included only a few studies for each outcome, we were unable to assess the presence of publication bias through formal testing. </p> <p>Furthermore, some papers may have been misclassified as not eligible for inclusion in this review. Two review authors independently assessed all studies, and a third review author verified the data; we are confident that we assessed studies excluded from analyses on the basis of consistent and appropriate criteria. For some full‐text reports, it is possible that we could have entered some data into analyses incorrectly, although we double‐checked all data to attempt to avoid extraction errors. </p> <p>We contacted the investigators of three included studies based on conference proceedings that were available as an abstract, to obtain study characteristics and other numerical outcome data. Although we received responses from all of these investigators, we found that data from only two studies were provided. The same investigator was involved in both of these studies, which were conducted in similar settings and used similar interventions. Owing to the small number of included studies, we did not explore the impact of excluding studies with missing outcome data in the overall assessment of results by performing a sensitivity analysis. Finally, data were insufficient to permit all planned subgroup analyses, so we included only types of antibiotics, which we considered most clinically important. </p> </section> <section id="CD012406-sec-0119"> <h3 class="title" id="CD012406-sec-0119">Agreements and disagreements with other studies or reviews</h3> <p>Major findings of the present review are largely in agreement with the results of previously published meta‐analyses of the impact of macrolides on outcomes in bronchiectasis (<a href="./references#CD012406-bbs2-0035" title="GaoY‐H , GuanW‐J , XuG , TangY , GaoY , LinZ‐y , et al. Macrolide therapy in adults and children with non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. PLoS One 9;3:e90047. ">Gao 2014</a>), which have shown a reduced frequency of exacerbations, improved lung function, and improved quality of life with prolonged macrolide treatment. Differences in effect size between our present review and these previously published meta‐analyses reflect differences in the inclusion and exclusion criteria of studies, as well as the inclusion of some recent studies. In general, the strict methods applied in the present review have resulted in pooling of fewer studies and therefore more precise effect estimates. </p> <p>The three largest macrolide trials have the longest duration of follow‐up and are concordant with overall results of the meta‐analysis, with each demonstrating benefit in terms of frequency of and/or time to first exacerbation (<a href="./references#CD012406-bbs2-0001" title="AltenburgJ , WilmsE , BoersmaW . The relationship between serum‐ and sputum levels of azithromycin and clinical endpoints in bronchiectasis patients in bronchiectasis patients using maintenance treatment. Pneumologie. 2016; Vol. 70:A3. [DOI: 10.1055/s‐0036‐1592227] AltenburgJ , WolfR , GoS , vanRijnP , BoersmaW , van derWerfT . Changes of computed tomography features of bronchiectasis during one year of azithromycin treatment. European Respiratory Journal. 2016; Vol. 48:OA278. [DOI: 10.1183/13993003.congress‐2016.OA278] AltenburgJ , deGraafC , van derWerfT , BoersmaW . Long term azithromycin treatment: A randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Journal. 2011; Vol. 38:1924. AltenburgJ , deGraafCS , SteinstraY , SloosJH , vanHarenEH , KoppersRJ , et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA2013;309(12):1251‐9. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QoL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A3658. ">Altenburg 2013</a>; <a href="./references#CD012406-bbs2-0012" title="BurrL , RogersG , TaylorS , McGuckinM , SerisierD . Sub inhibitory erythromycin reduces the expression of key P. Aeruginosa virulence determinants in non‐CF bronchiectasis subjects. Respirology. 2015:29. BurrLD , RogersGB , ChenAC , HamiltonBR , PoolGF , TaylorSL , et al. Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non‐cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low‐dose erythromycin study trial. Annals of the American Thoracic Society2016;13(10):1697‐703. [PUBMED: 27464029] ChenAC , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Journal of Respiratory and Critical Care Medicine. 2013; Vol. 187:A5970. RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . Corrections. The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2015; Vol. 3, issue 4:e15. [PUBMED: 25890660] RogersGB , BruceKD , MartinML , BurrLD , SerisierDJ . The effect of long‐term macrolide treatment on respiratory microbiota composition in non‐cystic fibrosis bronchiectasis: an analysis from the randomised, double‐blind, placebo‐controlled BLESS trial. Lancet Respiratory Medicine2014;2(12):988‐96. [PUBMED: 25458200] SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieA , MartinML . Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012; Vol. 185:A6862. SerisierDJ , MartinML , McGuckinMA , LourieR , ChenAC , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA2013;309(12):1260‐7. [PUBMED: 23532242] ">Serisier 2013</a>; <a href="./references#CD012406-bbs2-0014" title="WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbations in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380(9842):660‐7. [PUBMED: 22901887] WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 2012a; Vol. 185:A3657. ">Wong 2012</a>). It is striking that all three studies are of high quality (<a href="#CD012406-fig-0004">Figure 4</a>). </p> <p>The benefit in terms of exacerbations was largely attributable to azithromycin. This should not be taken to indicate that azithromycin is superior to other macrolides because the characteristics of participants in the BLESS study of erythromycin were different from those of participants enrolled in azithromycin studies. Our analysis is not designed to determine whether the drug or the patient cohort is responsible for the apparent differential effect. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012406-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012406-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/full#CD012406-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Global distribution of studies." data-id="CD012406-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Global distribution of studies.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/full#CD012406-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012406-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/full#CD012406-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012406-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/full#CD012406-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Analysis 1.1. Cates plot showing the absolute reduction in numbers of participants experiencing one or more exacerbations in adults treated with macrolides compared with placebo (OR 0.34, 95% CI 0.22 to 0.54). 714 people per 1000 in the placebo group experienced one or more exacerbations compared with 459 (95% CI 355 to 574) per 1000 in the macrolide group." data-id="CD012406-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Analysis 1.1. Cates plot showing the absolute reduction in numbers of participants experiencing one or more exacerbations in adults treated with macrolides compared with placebo (OR 0.34, 95% CI 0.22 to 0.54). 714 people per 1000 in the placebo group experienced one or more exacerbations compared with 459 (95% CI 355 to 574) per 1000 in the macrolide group. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/full#CD012406-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Macrolide versus placebo: adults, Outcome 1 ≥ 1 exacerbation." data-id="CD012406-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Macrolide versus placebo: adults, Outcome 1 ≥ 1 exacerbation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Macrolide versus placebo: adults, Outcome 2 Hospitalisation: all‐cause." data-id="CD012406-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Macrolide versus placebo: adults, Outcome 2 Hospitalisation: all‐cause.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Macrolide versus placebo: adults, Outcome 3 Serious adverse events." data-id="CD012406-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Macrolide versus placebo: adults, Outcome 3 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Macrolide versus placebo: adults, Outcome 4 Sputum weight (g): endpoint." data-id="CD012406-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Macrolide versus placebo: adults, Outcome 4 Sputum weight (g): endpoint.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Macrolide versus placebo: adults, Outcome 5 FEV1 (% predicted): endpoint." data-id="CD012406-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Macrolide versus placebo: adults, Outcome 5 FEV<sub>1</sub> (% predicted): endpoint. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Macrolide versus placebo: adults, Outcome 6 FEV1 (% predicted): change (post bronchodilator)." data-id="CD012406-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Macrolide versus placebo: adults, Outcome 6 FEV<sub>1</sub> (% predicted): change (post bronchodilator). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Macrolide versus placebo: adults, Outcome 7 FEV1 (L): endpoint." data-id="CD012406-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Macrolide versus placebo: adults, Outcome 7 FEV<sub>1</sub> (L): endpoint. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Macrolide versus placebo: adults, Outcome 8 FEV1 (L): change." data-id="CD012406-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Macrolide versus placebo: adults, Outcome 8 FEV<sub>1</sub> (L): change. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Macrolide versus placebo: adults, Outcome 9 FVC (% predicted): endpoint." data-id="CD012406-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Macrolide versus placebo: adults, Outcome 9 FVC (% predicted): endpoint.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Macrolide versus placebo: adults, Outcome 10 FVC (L): endpoint." data-id="CD012406-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Macrolide versus placebo: adults, Outcome 10 FVC (L): endpoint.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Macrolide versus placebo: adults, Outcome 11 FVC (L): change." data-id="CD012406-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Macrolide versus placebo: adults, Outcome 11 FVC (L): change.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Macrolide versus placebo: adults, Outcome 12 FEV1/FVC: endpoint." data-id="CD012406-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Macrolide versus placebo: adults, Outcome 12 FEV<sub>1</sub>/FVC: endpoint. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Macrolide versus placebo: adults, Outcome 13 Adverse events." data-id="CD012406-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Macrolide versus placebo: adults, Outcome 13 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Macrolide versus placebo: adults, Outcome 14 Azithromycin‐resistant bacteria (any)." data-id="CD012406-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Macrolide versus placebo: adults, Outcome 14 Azithromycin‐resistant bacteria (any). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Macrolide versus placebo: adults, Outcome 15 6‐Minute walk test: change." data-id="CD012406-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Macrolide versus placebo: adults, Outcome 15 6‐Minute walk test: change.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Macrolide versus placebo: adults, Outcome 16 Quality of life: endpoint." data-id="CD012406-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Macrolide versus placebo: adults, Outcome 16 Quality of life: endpoint.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Macrolide versus placebo: adults, Outcome 17 Quality of life: change." data-id="CD012406-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Macrolide versus placebo: adults, Outcome 17 Quality of life: change.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Macrolide versus no intervention: adults, Outcome 1 ≥ 1 exacerbation." data-id="CD012406-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Macrolide versus no intervention: adults, Outcome 1 ≥ 1 exacerbation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Macrolide versus no intervention: adults, Outcome 2 QoL SGRQ: endpoint total score." data-id="CD012406-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Macrolide versus no intervention: adults, Outcome 2 QoL SGRQ: endpoint total score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Macrolide versus placebo: children, Outcome 1 Hospitalisation: all‐cause." data-id="CD012406-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Macrolide versus placebo: children, Outcome 1 Hospitalisation: all‐cause.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Macrolide versus placebo: children, Outcome 2 Serious adverse events." data-id="CD012406-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Macrolide versus placebo: children, Outcome 2 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Macrolide versus placebo: children, Outcome 3 Sputum purulence score: endpoint." data-id="CD012406-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Macrolide versus placebo: children, Outcome 3 Sputum purulence score: endpoint. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Macrolide versus placebo: children, Outcome 4 FEV1 (% predicted): endpoint." data-id="CD012406-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Macrolide versus placebo: children, Outcome 4 FEV<sub>1</sub> (% predicted): endpoint. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Macrolide versus placebo: children, Outcome 5 Adverse events." data-id="CD012406-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Macrolide versus placebo: children, Outcome 5 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Macrolide versus placebo: children, Outcome 6 Azithromycin‐resistant bacteria (any)." data-id="CD012406-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Macrolide versus placebo: children, Outcome 6 Azithromycin‐resistant bacteria (any). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Macrolide versus placebo: children, Outcome 7 Azithromycin‐resistant Streptococcus pneumoniae." data-id="CD012406-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Macrolide versus placebo: children, Outcome 7 Azithromycin‐resistant Streptococcus pneumoniae. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012406-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/urn:x-wiley:14651858:media:CD012406:CD012406-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_t/tCD012406-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Macrolide versus placebo: children, Outcome 8 Azithromycin‐resistant Staphylococcus aureus." data-id="CD012406-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Macrolide versus placebo: children, Outcome 8 Azithromycin‐resistant Staphylococcus aureus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/media/CDSR/CD012406/image_n/nCD012406-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012406-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Macrolides compared with placebo for adults with bronchiectasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Macrolides compared with placebo for adults with bronchiectasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with bronchiectasis<br/> <b>Setting:</b> outpatient clinics in Australia, Azerbaijan, Malaysia, Netherlands, New Zealand, and Thailand<br/> <b>Intervention:</b> macrolides<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with macrolides</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 1 exacerbation<br/> Follow‐up: range 24 weeks to 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>714 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>459 per 1000<br/> (355 to 574) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.34<br/> (0.22 to 0.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies azithromycin (1750 mg/week for 52 weeks; 1500 mg/week for 6 months) 1 study erythromycin (3500 mg/week for 48 weeks) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation: all cause<br/> Follow‐up: range 12 weeks to 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>133 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000<br/> (28 to 200) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.56<br/> (0.19 to 1.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies azithromycin (1000 mg/week for 12 weeks; 1750 mg/week for 52 weeks)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/> Follow‐up: range 24 weeks to 48 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000<br/> (18 to 104) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.49<br/> (0.20 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>326<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies azithromycin (1500 mg/week for 6 months; 1000 mg/week for 12 weeks) 1 study erythromycin (3500 mg/week for 48 weeks) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality<br/> Follow‐up: range 8 weeks to 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>540<br/> (7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>e,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies azithromycin (1000 to 1750 mg/week for 12 to 52 weeks)<br/> 2 studies roxithromycin (2100 mg/week for 8 to 12 weeks)<br/> 1 study erythromycin (3500 mg/week for 48 weeks) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life: endpoint<br/> assessed with SGRQ<br/> Scale from 0 to 100<br/> Follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean SGRQ score at endpoint in placebo groups was 39.1 points.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 8.90 lower (13.13 lower to 4.67 lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<br/> (1 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study azithromycin (1000 mg/week for 12 weeks)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life: change<br/> assessed with SGRQ<br/> Scale from 0 to 100<br/> Follow‐up: range 8 weeks to 48 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in SGRQ score ranged from ‐1.3 to ‐8.9 points.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.86 lower<br/> (5.67 lower to 0.04 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>305<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>g,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study azithromycin (1500 mg/week for 6 months)<br/> 1 study erythromycin (3500 mg/week for 48 weeks)<br/> 2 studies roxithromycin (2100 mg/week for 12 weeks; 2100 mg/week for 8 weeks) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI</b> : confidence interval; <b>OR</b> : odds ratio; <b>RCT</b> : randomised controlled trial; <b>RR</b> : risk ratio; <b>SGRQ</b>: St. George's Respiratory Questionnaire. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Effect observed only with azithromycin (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> <p><sup>b</sup>Unclear allocation concealment and baseline imbalances on Lourdesamy (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> <p><sup>c</sup>Two small studies and wide confidence interval (one point deducted for imprecision). </p> <p><sup>d</sup>Wide confidence interval (one point deducted for imprecision). </p> <p><sup>e</sup>In three of the seven studies, study methods were not clearly reported (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> <p><sup>f</sup>A total of 28 participants across four studies were lost to follow‐up with no further details available and unclear details of withdrawals in one study (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> <p><sup>g</sup>Randomisation, blinding, and other study methods unclear in two studies (Asintam; Juthong) (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> <p><sup>h</sup>Wide confidence interval and mean difference does not exceed the threshold for clinical significance (one point deducted for imprecision). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Macrolides compared with placebo for adults with bronchiectasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/full#CD012406-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012406-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Macrolides compared with no intervention for adults with bronchiectasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Macrolides compared with no intervention for adults with bronchiectasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with bronchiectasis<br/> <b>Setting:</b> outpatient clinics in China and Spain<br/> <b>Intervention:</b> macrolides<br/> <b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with macrolides</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>≥ 1 exacerbation<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.31<br/> (0.08 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>43<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Roxithromycin (1050 mg/week for 6 months)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>762 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>498 per 1000<br/> (204 to 786) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisations ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality<br/> Follow‐up: range 3 months to 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No deaths in two trials, although in 1 study (azithromycin), 6 participants were lost to follow‐up </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study azithromycin (750 mg/week for 3 months)<br/> 1 study roxithromycin (1050 mg/week for 6 months) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QoL SGRQ: endpoint total score<br/> Scale from 0 to 100<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean SGRQ: endpoint total score of 51.7 points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 8.81 lower (14.33 lower to 3.28 lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89<br/> (2 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study roxithromycin (1050 mg/week for 6 months)<br/> 1 study roxithromycin (1050 mg/week for 6 months) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QoL SGRQ: change in total score<br/> Scale from 0 to 100<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean SGRQ: change in total score of 4.1</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 12 lower<br/> (21.61 lower to 2.39 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (750 mg/week for 3 months)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI</b> : confidence interval; <b>MD</b> : mean difference; <b>RCT</b> : randomised controlled trial; <b>RR</b> : risk ratio; <b>OR</b> : odds ratio; <b>QoL</b> : quality of life; <b>SGRQ</b>: St. George's Respiratory Questionnaire. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Open‐label study (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> <p><sup>b</sup>Unclear randomisation and study methods (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> <p><sup>c</sup>6 participants in one study lost to follow‐up and no further details reported (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Macrolides compared with no intervention for adults with bronchiectasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/full#CD012406-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012406-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Macrolides compared with placebo for children with bronchiectasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Macrolides compared with placebo for children with bronchiectasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children with bronchiectasis<br/> <b>Setting:</b> outpatient clinics in Australia, New Zealand, and South Africa<br/> <b>Intervention:</b> macrolides<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with macrolides</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation frequency</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Number of exacerbations 195 (median: 4 range 0‐14)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Number of exacerbations 104 (median: 2 range 0‐9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRR 0.50 95% CI 0.35 to 0.71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (30 mg/kg/week for up to 24 months)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation: all‐cause<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>205 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000<br/> (18 to 222) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.28<br/> (0.07 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (30 mg/kg/week for 24 months)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>432 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>246 per 1000<br/> (114 to 444) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.43<br/> (0.17 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (30 mg/kg/week for 24 months)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 child died but study group was not stated.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin (875 to 1750 mg/kg/week for 52 weeks)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI</b> : confidence interval; <b>IRR</b> : incidence rate ratio; <b>OR</b> : odds ratio; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Wide confidence interval that includes 1 (no difference) (one point deducted for imprecision). </p> <p><sup>b</sup>Low event rates and low numbers (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> <p><sup>c</sup>Unclear information on randomisation, blinding, and other study methods (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> <p><sup>d</sup>No information on participants lost to follow‐up (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Macrolides compared with placebo for children with bronchiectasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/full#CD012406-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012406-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Macrolides compared with no intervention for children with bronchiectasis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Macrolides compared with no intervention for children with bronchiectasis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children with bronchiectasis<br/> <b>Setting:</b> outpatient clinic in Turkey<br/> <b>Intervention:</b> macrolides<br/> <b>Comparison:</b> no intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no intervention</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with macrolides</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbations ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clarithromycin (105 mg/kg/week for 3 months)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI</b> : confidence interval; <b>RCT</b>: randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Insufficient information on study methods and procedures (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> <p><sup>b</sup>Not blinded (one point deducted in relation to design and implementation of available studies suggesting likelihood of bias). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Macrolides compared with no intervention for children with bronchiectasis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/full#CD012406-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012406-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adults/</b> </p> <p><b>Children</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of macrolide</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Macrolide dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Frequency</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Delivery mode</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Combined weekly dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration (months unless stated)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Altenburg 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1750 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asintam 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cymbala 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 days per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diego 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 days per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>750 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Juthong 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Koh 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liu 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin, ambroxol hydrochloride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1050 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ambroxol hydrochloride (no intervention)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liu 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1050 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lourdesamy 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Masekela 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 mg for children weighing &lt; 15 kg and 250 mg ≥ 15 kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>875 mg for children weighing &lt; 15 kg and 1750 mg ≥ 15 kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sadigov 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 days per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serisier 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Valery 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 mg/kg up to a maximum of 600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Once a week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 mg/kg up to a maximum of 600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wong 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 days per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yalcin 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clarithromycin, supportive therapies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Supportive therapies (no intervention)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/full#CD012406-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012406-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Macrolide versus placebo: adults</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 ≥ 1 exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.22, 0.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.13, 0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.34, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hospitalisation: all‐cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.19, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.19, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.20, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.20, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 8.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Sputum weight (g): endpoint <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 FEV<sub>1</sub> (% predicted): endpoint <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 FEV<sub>1</sub> (% predicted): change (post bronchodilator) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 FEV<sub>1</sub> (L): endpoint <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.17, 0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.23, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.27, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 FEV<sub>1</sub> (L): change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 FVC (% predicted): endpoint <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 FVC (L): endpoint <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.19, 0.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.34, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [‐0.16, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 FVC (L): change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 FEV<sub>1</sub>/FVC: endpoint <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.51, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.41, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.51, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Azithromycin‐resistant bacteria (any) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 6‐Minute walk test: change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Quality of life: endpoint <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.90 [‐13.13, ‐4.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.90 [‐13.13, ‐4.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Quality of life: change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.86 [‐5.67, ‐0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.25 [‐7.19, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.60 [‐7.12, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.86 [‐10.63, 6.91]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Macrolide versus placebo: adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012406-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Macrolide versus no intervention: adults</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 ≥ 1 exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 QoL SGRQ: endpoint total score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.81 [‐14.33, ‐3.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.81 [‐14.33, ‐3.28]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Macrolide versus no intervention: adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012406-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Macrolide versus placebo: children</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Hospitalisation: all‐cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Sputum purulence score: endpoint <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 FEV<sub>1</sub> (% predicted): endpoint <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [‐3.32, 6.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.70 [‐5.99, 13.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [‐4.91, 6.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Azithromycin‐resistant bacteria (any) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Azithromycin‐resistant Streptococcus pneumoniae <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Azithromycin‐resistant Staphylococcus aureus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Macrolide versus placebo: children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012406.pub2/references#CD012406-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012406.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012406-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012406-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD012406-note-0001">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012406\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012406\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012406\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012406\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012406\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012406\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012406\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012406\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012406\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012406\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012406\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012406\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012406\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012406\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012406\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012406\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012406\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012406\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZDBB8PHY&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012406.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012406.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012406.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012406.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012406.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714305497"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012406.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714305501"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012406.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6b736934f3cd',t:'MTc0MDcxNDMwNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 